CURRICULUM VITAE DATE OF PREPARATION: September 2, 2014 A. GENERAL INFORMATION

1. Name Ari Matthew Melnick 2. Home address 49 East 96th Street 4 C, NY, NY 10128 3. Home telephone 212-722-4046 4. Cell phone 917-532-0708 5. Email arimel@mac.com 6. Citizenship USA

B. EDUCATIONAL BACKGROUND:

Degree Institution and location Dates attended Date of award

High School Instituto Franklin, Buenos Aires, Argentina

1978-1982 1982

MD University of Buenos Aires School of Medicine

1983-1990 1990

C. PROFESSIONAL POSITIONS AND EMPLOYMENT: 1) Postdoctoral training

Title Institution name and location Dates held

Internal Medicine Resident Mount Sinai School of Medicine, New York, NY

1991-1994

Hematology/Oncology Fellow Mount Sinai School of Medicine, New York, NY

1994-1997

Post-Doctoral Fellow Mount Sinai School of Medicine, New York, NY

1997-2002

Visiting Post-Doctoral Fellow Sloan Kettering Institute, New York, NY 2001

2) Academic positions

Title Institution name and location Dates held

Instructor in Medicine Mount Sinai School of Medicine, New York, NY 1997-2001

Assistant Professor Mount Sinai School of Medicine, New York, NY 2001-2002

Assistant Professor Albert Einstein College of Medicine, Bronx, NY 2002-2007

Associate Professor Albert Einstein College of Medicine, Bronx, NY 2007-2008

Associate Professor Weil Cornell Medical College, New York, NY 2008-2012

Gebroe Family Professor of Hematology/Oncology

Weil Cornell Medical College, New York, NY 2013-present

3) Hospital positions

Title Institution name and location Dates held

Attending, Department of Emergence Medicine

Mount Sinai School of Medicine, New York, NY

1995-2000

Clinical Assistant, Department of Medicine

Mount Sinai School of Medicine, New York, NY

1997-2002

Assistant Professor of Oncology Albert Einstein College of Medicine, Bronx, NY

2002-2007

Associate Professor of Oncology Albert Einstein College of Medicine, Bronx, NY

2007-2008

D. LICENSURE, BOARD CERTIFICATION

1) Licensure

State Number Date of issue Last renewed

NY 197697 1994 2012

Federal DEA #: BM4597514

2) Board Certification

Name of Board Certificate # Date of issue

NY American Board of Internal Medicine 157247 1994

American Board of Internal Medicine - Hematology

157247 1997

American Board of Internal Medicine - Oncology

157247 1998

E. PROFESSIONAL SOCIETIES:

Member/Officer Name of Organization Dates Held

Member American Society of Hematology 1997-present

Member American Association of Cancer Research 1997-present

F. HONORS AND AWARDS: 1. House Staff Hero, Mount Sinai Medical Center, New York, NY. 1994 2. Best Teaching Fellow Award, Mount Sinai Medical Center, New York, NY. 1995 3. K08 mentored clinical scientist award. National Cancer Institute. 1997 CA73762. Mentor: J.D. Licht, MD. 4. American Society of Hematology Travel Award. 1998 5. New York Society of Medical Oncology Research Abstract Award. 1998 6. Berlex Foundation Research Award 1999 7. AACR-AFLAC Scholar in Cancer Research Award. 1999 8. American Society of Hematology Travel Award. 1999 9. American Society of Clinical Investigation Travel Award. 2001 10. Diane and Arthur B. Belfer Faculty Scholar in Cancer Research 2002 11. ASH Faculty Research Scholar 2002 12. Sidney Kimmel Scholar in Cancer Research 2003 13. ECOG/Aventis-Young Investigator Award in Translational Research 2004 14. Scholar of the Leukemia and Lymphoma Society 2006 15. Member of the American Society of Clinical Investigation 2009 16. Burroughs Wellcome Clinical Scientist Award 2009 17. Foreign Expert Scientist Award, People's Republic of China 2014

G. INSTITUTIONAL/HOSPITAL AFFILIATION Primary Hospital Affiliation: New York Presbyterian Hospital

H. EMPLOYMENT STATUS 1. Name of current employer: Weill Cornell Medical College 2. Employment status: Full time salaried by Weill Cornell Medical College

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT 1. Teaching Instructor of Biological Chemistry, University of Buenos Aires Medical School. 1985-1987 Instructor of Pharmacology, University of Buenos Aires Medical School. 1988-1990 Instructor of Pharmacology, Center for Medical Education 1989-1990

and Clinical Research. Buenos Aires. Instructor, Board Review Course for Internal Medicine. 1995-2002 Mount Sinai Medical Center, NYC. Lecturer and Instructor. Hematology Course for Second Year Medical 1995-2002 Students. Mount Sinai School of Medicine, NYC. Lecturer. Internal Medicine Core Curriculum for Medical Residents. 1995-2002 Mount Sinai Medical Center, NYC. Supervisor. Hematology Consult Service. Mount Sinai Medical 1997-2002 Center, NYC. Lecturer. Basic Science Core Curriculum for Hematology and 1997-2002 Oncology Fellows. Mount Sinai Medical Center, NYC. Director and Lecturer. Core Curriculum in Hematology and Oncology 1998-2002 for Hematology and Oncology Fellows. Mount Sinai Medical Center, NYC. Co-Director. Hematology/Oncology Fellowship Program. Mount 1998-1999 Sinai Medical Center, NYC. Director. Hematology/Oncology Fellowship Program. Mount Sinai 1999-2002 Medical Center, NYC. Lecturer - Hematology/Oncology Fellowship Program, Albert 2002-2008t Einstein College of Medicine Lecturer – Molecular Mechanisms of Disease - Albert 2004-2008 Einstein College of Medicine Lecturer – Cancer Biology course – Albert Einstein College of Medicine 2005-2008 Lecturer – Advanced Molecular Genetics – Albert Einstein College of Medicine 2006-2008 Co-Leader – Cross campus program for graduate students in computational 2009-present Biostatistics, Cornell University Lecturer – Weill Cornell Medical College – Translational Medicine (Med School) 2010-present Lecturer – Weill Cornell Medical College – Pulmonary Genetics (Grad School) 2010-present Visiting Professor – Erasmus Medical College 2014 2. Clinical care Emergency Room Attending (Mount Sinai) 1995-2000 Hematology/BMT Inpatient Service (Mount Sinai) 1997-2002 Hematology Clinic Supervisor (Mount Sinai) 1999-2002 Guest Attending- Medical Intensive Care Unit (Mount Sinai) 1997-2002 3. Administrative duties Fellowship Quality Assurance Committee, Dept. of Medicine, 1998-2002 Mount Sinai Medical Center Graduate School Recruitment Committee. Albert Einstein College of Medicine. 2002-2003 Co-leader. Transcriptional Activation and Repression Group (TARG). 2002-present Albert Einstein College of Medicine Graduate School representative of the Developmental and Molecular 2003-2005 Biology Dept. Albert Einstein College of Medicine Hematology/Oncology Fellowship Training Committee. Albert 2003-2008 Einstein College of Medicine. NimbleGen platform resource management committee, Albert 2003-2008 Einstein College of Medicine. Microarray Committee, Albert Einstein College of Medicine. 2004-2008 Co-leader. Immuno-Oncology Program, Albert Einstein College of Medicine 2004-2008 Co-leader. Translational Epigenomics Program. Albert Einstein College of 2005-2008 Medicine.

Dean’s strategic planning task force, Albert Einstein College of Medicine 2006-2007 Cancer Center Steering Committee, Albert Einstein College of Medicine 2006-2008 WCMC Cancer Center Core Facilities Committee 2008-2011 Co-Director, WCMC Medical Residency Research Track 2009-2013 Faculty director. Weill Cornell Epigenomics Core Facility 2008-present Director, Sackler Center for Biomedical and Physical Sciences, WCMC 2009-present Co-Leader, NYC Leukemia Working Group 2009-present Bridge Fund Committee 2013-present Chair, Hematologic Malignancies Program, WCMC 2013-present CoChair, Genetics and Epigenomics Program, WCMC 2013-present Multiple ad-hoc search committees 2010-present 4. Research Transcriptional programming, therapeutic targeting and epigenomics 2002-present of hematologic malignancies

Current percent effort Teaching 5% Clinical 0% Administrative 50% Research 45%

5. Mentoring 1. Mentoring Junior Faculty Sarah Lo, MD, Department of Pediatrics, division of pediatric hematology/oncology Jia Ruan, MD, Division of Hematology/Oncology Rebecca Elstrom, MD, Division of Hematology/Oncology Monica Guzman, PhD, Division of Hematology/Oncology Lucy Skrabanek, PhD, Institute for Computational Biomedicine Olivier Elemento, PhD, Institute for Computational Biomedicine Christopher Mason, PhD, Institute for Computational Biomedicine Yariv Houvras, MD, PhD, Division of Hematology/Oncology Doron Betel, PhD, Institute for Computational Biomedicine Leandro Cerchietti, MD, Division of Hematology/Oncology Rita Shaknovich, MD PhD, Department of Pathology Effie Apostolou, PhD, Division of Hematology/Oncology 2. Current Trainees

Matthew Teater Graduate Student Tharu Ferrando Graduate student NRSA funded Rebecca Goldstein Graduate student

NRSA funded Rajat Singh Graduate student Katerina Chatzi, MS Post-doctoral fellow

Yanwen Jiang, PhD Post-doctoral fellow ASH Scholar Award Lorena Fontan, PhD Post-doctoral fellow LRF fellow award Meng Li, PhD Post-doctoral fellow Cem Meydan, PhD Post-doctoral fellow Cihangir Duy, PhD Post-doctoral fellow LLS Fellow Fang Fang, PhD Post-doctoral fellow Wendy Béguelin, PhD Revson Fellow ASH Scholar

Isaac Boss, PhD Post-doctoral fellow Sass Fellow Jacob Glass, MD, PhD Heme-Onc Fellow (MSKCC) ASH Trainee award Francine Garret-Bakelman, MD PhD Instructor K08 funded, RWJ Fellow 3. Former Post-doctoral fellows and students:

Chuanxin Huang, PhD (former post-doc) Assistant Professor Department of Cell Biology

Shanghai Jiao Tong University School of Medicine

Karen Bunting, PhD (former post-doc) Project Manager New York Genome Center Leandro Cerchietti, MD (former post-doc) Assistant Professor, Weill Cornell Medical College Sackler Foundation Scholar NCI faculty development award Maria Figueroa, MD (former post-doc) Assistant Professor, Department of Pathology University of Michigan Leukemia and Lymphoma Society Special Fellow Sass Foundation Fellow Scholar of the American Society of Hematology Doris Duke Foundation Scholar Award Weili Sun, MD PhD (former post-doc) Assistant Professor, Division of Pediatric Hematology-Oncology University of Southern California Norris Comprehensive Cancer Center Rita Shaknovich, MD PhD (former post-doc) Assistant Professor, Department of Pathology, Weill Cornell Medical College K08 Mentored Physician Scientist Career Development Award LLS Translational Research Program Award Samir Parekh, MD (former post-doc) Associate Professor, Department of Medicine, Mount Sinai School of Medicine ASCO Young Investigator Award LLS Translational Research Program Award Chemotherapy Foundation Award Weimin Ci, PhD (former post-doc) Assistant Professor, Beijing Institute of Genomics, Chinese Academy of Medical Sciences Fan Guo Meng, PhD (former post-doc) Assistant Professor, Tsing Hua University, China

Huimin Geng, PhD (former post-doc) Instructor University of California San Francisco (UCSF)

Stella Maris Ranuncolo, MDPhD (former post-doc) Assistant Professor University of Buenos Aires School of Medicine Eloisi Caldas Lopes, PhD (former post-doc) Staff Scientist, Memorial Sloan Kettering Jose Ignacio Martinez, PhD (former post-doc) Instructor and laboratory head University of Valencia, Spain. Former post-doctoral Fellow Spanish Government Research Fellow Award Thomas Clozel, MD (former Visiting post-doctoral fellow) Hematology Oncology fellow at Hopital St Louis, Paris ASH travel award Ester Valls, PhD (former post-doc) Post-doctoral fellow, Experimental Medicine Center, Barcelona Former Post-doctoral Fellow Spanish Government Research Fellow Award Tania Dell’Oso PhD (former post-doc) Genzyme Corporation. Irina Velichutina, PhD (former post-doc) Lymphoma Research Foundation Fellow Jose Polo, PhD (former graduate student) Post-doc: Konrad Hochedlinger, Harvard University Current: Associate Professor Monash Institute Melbourne Australia NCCC fellowship 2004 ASH Merit Award

4. Other trainees: Alka Malik, MD Hematology-Oncology fellow Santiago Aparna, MD Resident Internal Medicine Ana Antun, MD Resident Internal Medicine ASH Trainee award Cristoph Hueck, MD Resident Internal Medicine

Jennifer Amengual, MD Resident Internal Medicine Adriana Milillo, MD Resident Internal Medicine ASH Trainee award Mark Rappaport, MD Resident Internal Medicine Yelena Krupitskaya, MD Resident Internal Medicine Mahesh Seetharam, MD Resident Internal Medicine Sebastian Mayer, MD Resident Internal Medicine Gustavo Da Silva, PhD Visiting Scientist 2006 ASH Merit Award Paola Lev, PhD Visiting Post-Doctoral Fellow HFSP Fellowship Award ASH Trainee award Erdogan Taskesen, PhD Visiting Post-Doctoral Fellow HFSP Fellowship Award Saane Lughtart, PhD Visiting Post-Doctoral Fellow HFSP Fellowship Award Maria Perez Caro, PhD Visiting Post-doctoral Fellow HFSP Fellowship Award

David Beck Undergraduate student Zev Hamburger Undergraduate student Itamar Niesvizky Undergraduate student Ben Biran Undergraduate student

Adeeti Aggarwal Undergraduate student Teresa Rubio Undergraduate student Jared Frank High School Student. Sofia Iaffa High School Student Megan Ryan High School Student ASH Merit Award – 2006 – and Oral presentation

J. RESEARCH SUPPORT Past Research Support: NCI K08 Mentored Clinical Scientist Award NCI R21 The BTB pocket as a novel cancer therapy agent ASH Faculty Scholar Award Kimmel Scholar in Cancer Research Basil O’Connor Scholar of the March of Dimes G&P Foundation Research Grant Current Research Support: R01 R01CA155226 (Melnick, PI) 03/01/2011-2/29/2016 NIH/NCI Annual Direct Costs: $136,265 Effort: 1.2 Calendar Title: “ Targeting the heat shock response for the therapy of DLBCL” Goal: Determine the client proteins and optimal means for targeting Hsp90 in DLBCL

R01 CA104348-09 (Melnick, PI) 06/01/2010-05/31/2015 NIH/NCI Annual Direct Costs: $144,285 Effort: 0.60 Calendar Title: “Transcriptional silencing by the Bcl-6 oncoprotein” Goal: Decode the transcriptional mechanism of action of BCL6 in B-cells R01 CA187492 (Melnick, PI) 08/01/2014-7/31/2019

National Cancer Institute Annual Direct Costs: $207,500 Effort: 1.20 Calendar Title: MALT1 Targeted Therapy for B-cell lymphoma Goal: To determine the mechanism of action of MALT1 inhibitors in DLBCLs and other lymphomas.

R01 CA187109 (Melnick, PI) 08/01/2014-7/31/2019 National Cancer Institute Annual Direct Costs: $170,177 Effort: 1.20 Calendar Title: Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma Goal: To develop optimal therapeutic regimens for delivering EZH2 targeted therapy.

R01 CA182736 (Gray, Wu, Melnick (MPI)) 09/26/2013-8/31/2018 National Institutes of Health Annual Direct Costs: $124,133 Effort: 0.60 Calendar Title: MALT1 Inhibitors for the Treatment of Chemo-resistant ABC-DLBCL Note: This is a subcontract from Dana-Farber Cancer Center, and Dr. Melnick is Co-PI. Goal: To perform novel medicinal chemistry studies geared towards creating novel scaffolds with MALT1 inhibitor activity.

R01 NS076465 (Ross Elizabeth, PI) 09/01/2011-5/30/2016 NIH/NCI Annual Direct Costs: $1,797 Effort: 0.12 Calendar Title: “Epigenome interactions in Complex Neurogenetic Disorders” Goal: Define epigenomic marks that indicate enhanced risk of developing neural tube defects

R01 CA173636-01 (Levine, R PI) 2/01/2013-01/31/2018 National Cancer Institute Annual Direct Costs: $20,438 Effort: 0.36 Calendar Title: Role of TET2 mutations in malignant transformation and acute myeloid leukemia. Note: This is a subcontract from Memorial Sloan Kettering Cancer Center. Goal: To study mechanisms driving the phenotype of leukemias with TET2 mutations.

U10 CA180827 ( Paietta, PI) 4/01/2014-2/28/2019 National Institutes of Health Annual Direct Costs: $42,977 Effort: 0.36 Calendar Title: "ECOG-ACRIN Integrated Leukemia Translational Science Center" Goal: To develop framework to enable interactions between laboratory and clinical investigators, and provide pilot funding for novel scientific approaches to leukemia diagnosis and therapy. NNX14AH50G NASA Grant ( Mason, PI) 4/01/2014-4/14/2017 NASA Shared Services Center Annual Direct Costs: $1,815 Note: Provides only salary support to Dr. Melnick Effort: 0.12 Calendar Title: "The landscape of DNA and RNA Methylation before, during and after human space travel" Goal: The data will create a novel genome-wide characterization of the impact of space travel on

DNA/RNA meythlation and examine any potential risk.

LLS SCOR (Melnick PI) 10/01/2012-9/30/2017 LLS SCOR 7006-13 (Project 6) Annual Direct Costs: $150,000 Effort: 0.60 Calendar Title: “Epigenetic mechanisms contributing to leukemogenesis in elderly AML patients” Goal: To improve understanding of leukemic transformation in elderly patients in connection to the consequence of the loss of function of mechanisms that maintain the boundaries and chromosomal distribution of cytosine methylation.

LLS SCOR (Melnick PI) 10/01/2012-9/30/2017 LLS 7006-13 (Core C) Annual Direct Costs: $45,000 Effort: 0.24 Calendar Title: “Epigenetic mechanisms contributing to leukemogenesis in elderly AML patients” Goal: To improve understanding of leukemic transformation in elderly patients in connection to the consequence of the loss of function of mechanisms that maintain the boundaries and chromosomal distribution of cytosine methylation.

LLS Translational Research Program (Melnick, PI) 10/01/2014-9/30/2017 LLS 6457-15 Annual Direct Costs: $180,018 Effort: 0.12 Calendar Title: “Targeting Molecular Pathways Driving Follicular Lymphomas” Goal: To determine the mechanism through which TBLXR1 mutations drive FL pathogenesis

LLS Translational Research Program (Melnick, PI) LLS 6141-14 10/1/2013-9/30/2016 Annual Direct Costs: $180,018 Effort: 0.60 Calendar Title: "Rational Translation of EZH2 Targeted Therapy" Goal: To determin mechanisms of resistance that might attenuate response of lymphomas to EZH2 inhibitor drugs. Clinical Scientist Award in Translational Research (Melnick, PI) 7/01/2009-6/30/2015 Burroughs Wellcome Fund Annual Direct Costs: $150,000 Effort: 0.48 Calendar Title: “Differentiation therapy for B-cell lymphomas” Goal: Mechanism of action and therapeutic targeting of the MTA3 co-repressor in B-cell lymphomas.

Program Grant (Melnick, PI) 7/01/2014-6/30/2015 Samuel Waxman Cancer Research Foundation Title: Transcriptional targeting in cancer therapy Annual Direct Costs: $10,000 Effort: 0.12 Calendar Goal: Test the biological activity of CADD designed small molecules of Kaiso. Research Grant (Melnick, PI) 1/01/2014-12/31/2015

Chemotherapy Foundation Annual Direct Costs: $54,545 Effort: 0.12 Calendar Title: “Transcriptional regulation by hematopoietic BTB transcription factors” Goal: Explore roles of BTB domain transcription factors in hematologic malignancies.

Starr Cancer Consortium Grant (Lou, PI) 1/01/2013-12/31/2015 Starr Foundation I6-A622 Annual Direct Costs: $50,000 Effort: 0.24 Calendar Title: “Define Oncogenic Mechanisms of Protein Methyltransferase SETDB1 and AUV39H1 in Melanoma” Goal: To explore the role of SETDB1/SUV39H1 on target genes throughout the genome, and their effects on histone methylation patterning.

Starr Cancer Consortium Grant (Schwartz, PI) 1/01/2013-12/31/2015 Starr Foundation I6-A616 Annual Direct Costs: $166,889 Effort: 0.24 Calendar Title: “Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma” Goal: To perform epigenomics studies including ERRBS, ChIP-seq and other assays to identify the genes and genomic regions that are perturbed in tumors bearing somatic mutations in IDH enzymes. Tri-Stem ( Park, PI) 7/01/2013-6/30/2015 Tri-Institutional Stem Cell Initiative Annual Direct Costs: $25,000 Effort: 0.24 Calendar Title: "Translational Regulation in Hematopoietic Stem Cells" Goal: To identify polysome bound RNAs in hematopoietic stem cells and whether perturbation of translation machinery perturbs these profiles. Tri-Stem ( Park, PI) 8/01/2014-7/31/2017 Tri-Institutional Stem Cell Initiative Annual Direct Costs: $83,333 Effort: 0.24 Calendar Title: " Hematopoietic Stem Cell Origins of Mature B-cell Neoplasms" Goal: To Investigate the role of HSCs in the pathogenesis of mature B-cell malignancies. ECRIP ( Melnick, PI) 1/15/2014-01/15/2016 Empire Clinical Research Investigator Program Annual Direct Costs: $267,576 Effort: 0.12 Calendar Title: "Center for lymphoma and Blood Therapeutics" Goal: To train clinical investigators in Heme Malignancies. Sohn Collaborative Research Grant ( Melnick, PI) 4/22/2014-4/21/2016 Sohn Conference Foundation Annual Direct Costs: $35,025 Effort: 0.12 Calendar

Title: "Sohn Collaborative Project" Goal: To perform epigenomic assays on tumor specimen. Janssen BCL6 Research Alliance ( Melnick, PI) 6/10/2014-6/30/2015 Janssen Biotech Annual Direct Costs: $144,425 Effort: 0.12 Calendar Title: "Janssen Collaborative Project" Goal: To identify potent and selective drug-like inhibitor that can be used to treat lymphomas in human patients. Janssen MALT1 Research Alliance ( Melnick, PI) 12/17/14-12/17/2017 Janssen Biotech Annual Direct Costs: $677,852 Effort: 0.36 Calendar Title: "Janssen MALT1 Collaborative Project" Goal: To discover new small molecule inhibitors of MALT1 and perform a comprehensive study of their pharmacodynamics, effectiveness, biomarkers of response and combinatorial treatment.

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES 1. External committees and advisory boards American Society of Hematology Committee on Training Programs 2001-2005 National Curriculum for Hematology Fellowship Subcommittee 2001-2005 for the American Society of Hematology. ACGME guidelines for hematology/oncology fellowship programs 2001-2005 subcommittee for the American Society of Hematology National Trainee Council Supervisory Subcommittee for the 2001-2005 American Society of Hematology. Graduate School Advisory Committee, Universidad 2002-2006 Nacional de Quilmes, Argentina. Member, ECOG Leukemia Laboratory Committee 2004-2005 NCI/NHLBI Steering committee for clinical and translational studies 2005-2006 on myelodysplasias Chair of ECOG Leukemia Laboratory Science Committee 2005-present Mantle cell lymphoma P01 external advisor, Moffit Cancer 2006-2012 Center, University of Southern Florida, Tampa, FL American Society of Hematology – Awards Committee 2006-2009 American Society of Hematology – Program Committee 2006-2009 Scientific Advisory Board of the Lymphoma Research Foundation (LRF) 2007-present Executive Committee for Follicular Lymphoma Research, LRF 2008-2013 Executive Committee of the SAB, LRF 2010-2013 Chair, Awards Committee, LRF 2010-2013 External Advisory Board, Lymphoma SPORE MD Anderson 2010-2014 AACR program committee 2011-2014 NCI Lymphoma Steering Committee 2014-present

2. Editorial Review:

• Cancer Research – Associate Editor (2008 – 2010) • Leukemia - Special Editor of Spotlight Issue on “Controversies in APL” • Leukemia – Section Editor (2002 – 2009) • Oncogene - reviewer • Blood – reviewer • Cell – reviewer • Molecular and Cellular Biology – reviewer • Clinical Cancer Research – reviewer • Journal of Hematology – reviewer • Molecular Cell - reviewer • Journal of Clinical Investigation – reviewer • American Society of Hematology – reviewer of abstracts for the national meeting • American Association of Cancer Research – reviewer of abstracts for national meeting • Leukemia Forum 2005 – San Francisco, CA. • Nature Medicine – reviewer • Cancer Cell – reviewer • Nature – reviewer • Science Translational Research – reviewer • Journal of Experimental Medicine - reviewer • American Journal of Pathology – reviewer • Genome Research – reviewer • British Journal of Hematology – reviewer • Nature Genetics – reviewer • Current Opinion in Hematology – section editor (2013-2018) • Cancer Discovery Scientific Editor (2014 - present) 3. Grant Review panels: Congressionally Mandated Research Program on Chronic Myeloid Leukemia. 2002 NCI ad-hoc committee for review of P01 Leukemia Program Project Grant. 2003 Congressionally Mandated Research Program on Chronic Myeloid Leukemia. 2004 NCI Committee G Study Section – Ad Hoc member 2004-2005 Dutch Cancer Society 2005-2008 NCI MONC Study Section ad hoc member 2006 Prostate Cancer Foundation 2008 Cancer Research UK 2008 NCI CAMP study section ad hoc member 2010-2011 Lymphoma Research Foundation 2007-present Leukemia and Lymphoma Society of America 2006-present Sam Waxman Cancer Research Foundation Study Section 2005-present NCI CAMP study section standing member 2011-present 4. Meeting Organizer:

Organizing committee. ASCO symposium on DLBCL therapeutics. 2007. Aspen, CO. Chair, Scientific Program. Annual Meeting of the American Society of Hematology. 2007. Atlanta, GA. Organizer, ASH Highlights meeting, 2008. Austin TX. Organizer. ASH Highlights meeting, 2008. Seattle, WA. Organizer. Clinical Epigenetics Meeting, 2009. Coral Gables, FL.

Organizer. FASEB meeting on hematologic malignancies. 2009. Saxtons River, VT. Organizer. Clinical Epigenetics Meeting, 2011. San Diego, CA. Organizer. Clinical Epigenetics Meeting, 2013. Asheville, North Carolina. Organizer. ASH Lymphoma Biology Meeting, 2014. Colorado Springs, CO. Program Committee. AACR Hematologic Malignancies Meeting, 2014. Philadelphia, PA. Organizer. Clinical Epigenetics Meeting. 2015. Saint Augustine, FL. Scientific Program Committee, 2014 AACR Annual Meeting, Philadelphia, PA

L. BIBLIOGRAPHY 1. Articles Published or In Press in Peer Reviewed Journals. 1. X Agirre, G Castellano, M Pascual, S Heath, M Kulis, V Segura, A Bergmann, A Esteve, A Merkel,

E Raineri, L Agueda, J BLanc, D Richardson, L Clarke, A Datta, N Russinol, AC Queiros, R Beekman, JR Rodriguez-Madoz, E San Jose-Eneriz, F Fang, NC Gutierrez, JM Garcia-Verdugo, MI Robson, EC Schirmer, E Guruceaga, JHA Martens, N GZut, MJ Calasanz, P Flicek, R Sibert, E Campo, JF San Miguel, A Melnick, HG Stunnenberg, IG Gut, F Prosper, JI Martin. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. 2015. Genome Research. In Press.

2. Z Chen, S Shojaee, M Buchner, H Geng, JW Lee, L Klemm, B Titz, T Graeber, C Lowell, E Paietta, S Hunger, C Willman, A Melnick, M Loh, J Jung, J Coligan, S Bolland, T Mak, A Limnander, H Jumaa, M Reth, A Weiss, C Lowell, M Muschen. Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia. 2014. Nature. In Press.

3. SM Park, M Gonen, L Vu, G Minuesa, P Tivnan, TS barlowe, J Taggart Y Lu, RP Deering, N Hacohen, ME Figueroa, E paiettal, MS tallman, A Melnick, RL Levine, C Leslie, CJ lengner, MG Kharas. Msi2 is required to sustain the MLL leukemia stem cell regulatory program. J Clin Investigation. In Press.

4. F Garrett-Bakelman, C Sheridan, TJ Kacmarczyk, J Ishii, A Alonso, A Melnick. Enhanced Reduced Representation Bisulfite Sequencing for assessment of DNA methylation at base pair resolution. 2014. JoVE. In Press

5. J Van der Meulen, V Sanghvi, K Mavrakis, K Durinck, F Fang, F Matthijssens, P Rondou, P Vendenberghe, E Delabesse, T Lammens, B De Moerloose, B menten, N Van Roy, B Berhasselt, B Poppe, Y Benoit, T Taghon, A Melnick, F Speleman, HG Wendel, P Van Vlierberghe. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. 2015. Blood. 125(1):13-21.

6. RG Patel, A Purwada, L Cerchietti, G Inghirami, A Melnick, A Gharwar, A Singh. Microscale bioadhesive hydrogels arrays for cell engineering applications. 2014. Cellular and Molecular Bioengineering. 7(3):394-408.

7. R Rampal, A Vasanthakumar, ME Figueroa, J Madzo, J Patel, O Abdel-Wahab, JB Lepore, A Shih, C Lu, PS Ward, JJ Tsai, T Hrcik, Y li, V Tosello, X Zhao, CX Song, Q Dai, D Pollyea, C He, F Fuks, MS Tallman, E Paietta, SD Nimer, M Carroll, I Aifantis, CB Thompson, JD Licht, A Ferrando, LA Godley, A Melnick*, ME Figueroa, RL Levine. WT1 mutations result in impaired TET2 function and dysregulated hydroxymethylation in acute myeloid leukemia. 2014. Cell Reports. 9(5):1841-55. * Corresponding Author.

8. SS Chung, E Kim, JH Park, YR Chung, P Lito, J Teruya-Feldstein, W Hu, W Beguelin, S Monette, C Duy, R Rampal, L Telis, M Patel, MK Kim, K Huberman, N Bouvier, MF Berger, A Melnick, N Rosen, MS Tallman, CY Park, O Abdel-Wahab. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014 May 28;6(238):238ra71.

9. S Li, F Garrett-Bakelman, AE Perl, S Luger, T Hricik, C Zhang, M Ross, RL Levine, M Carroll, A Melnick*, CE Mason. Dynamic Evolution of Clonal Epialleles Revealed by Methclone. 2014. Genome Biology.15(9):472. * Corresponding Author.

10. C Huang, DG Gonzalez, CM Cole, Y Jiang, K Hatzi, M Teater, K Dai, T Hla, AM Habermann, A Melnick. The BCL6 RD2 domain governs commitment of activated B-cells to form germinal centers 2014. Cell Reports. 8(5):1497-508. Cited by Faculty of 1000.

11. Y Jiang, D Redmond, K Nie, T Clozel, P Martin, LHC Tan, A Melnick, W Tam, O Elemento. Deep sequencing reveals distinct clonal evolution patterns of DLBCL relapse and mutation events associated with relapse in B cell lymphomas. 2014. Genome Biology. 15(8):432.

12. K Ha, W Fiskus, DS Choi, S Bhaskara, L Cerchietti, SGT Deveraj, K Liu, S Sharma, J Chiang, A Melnick, S Hiebert, KN Bhalla. Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. 2014. Oncotarget. 5(14):5637-50.

13. A Rodina, T Taldone, Y Kang, P Patel, J Koren, P Yan, E Gomes, C Yang, M Patel, L Shrestha, S Ochiana, C Santarossa, R Maharaj, A Gozman, M Cox, H Bromage, R Hendrickson, M Guzman, L Cerchietti, A Melnick, G Chiosis. Affinity-purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. 2014. ACS Chemical Biology. 9(8):1698-705.

14. B Kharabi Masouleh, H Geng, C Hurtz, C Huang, LN Chan, S Swaminanthan, H Sun, A Melnick, E Paietta, HP Koeffler, M Müschen. A mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia". 2014. PNAS. 111(21):E2219-28.

15. MR Green, C Vicente-Duenas, I Romero-Camarero, C Long Liu, I Gonzalez-Herrero, I Garcia-Ramirez, E Alonso-Escudero, J Iqbal, WC Chan, E Campos-Sanchez, A Orfao, B Pintado, T Flores, O Blanco, R Jimenez, JA Martinez-Climent, FJ Garcia Criado, MB Garcia Cenador, S Zhao, Y Natkunam, IS Lossos, A Melnick, C Cobaleda, AA Alizadeh, I Sanchez-Garcia. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. 2014, Nature Communications. Jun 2;5:3904. doi: 10.1038/ncomms4904.

16. CJ Kemp, JM Moore, R Moser, B Bernard, M Teater, LE Smith, N Rabaia, KE Gurley, SE Busch, R Shaknovich, VV Lobanenkov, D Liggit, I Shmulevich, A Melnick. GN Filippova. Genetic disruption of CTCF destabilizes DNA methylation and accelerates cancer progression. 2014. Cell Reports. 7(4):1020-9.

17. E Taskesen, M Havermans, K Van Lom, M Sanders, Y Van Norden, E Bindels, R Hoogenboezem, MJT Reinders, ME Figueroa, PJM Valk, B Lowenberg, A Melnick, R Delwel. Two splice factors mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA methylation profiling. 2014. Blood. 123(21):3327-35.

18. W Fiskus, N Saba, M Shen, M Ghias, S Das Gupta, L Chauhan, R Rao, S Gunewarda, K Schorno, C Austin, K Maddocks, JC Byrd, A Melnick, P Huang, A Wiestner, KN Bhalla. Auranofin has potent pre-clinical activity against chronic lymphocytic leukemia through induction of lethal oxidative and endoplasmic reticulum stress. 2014. Cancer Research.74(9):2520-32.

19. SS. Chung, Kim, J Park, YR Chung, P Lito, J Feldstein, W Hu, W Beguelin, C Duy, R Rampal, L Telis, M Patel, MK Kim, A Melnick, N Rosen, MS Tallman, CY Park, O Abdel-Wahab. Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia. 2014. Science Translational Medicine. May 28;6(238):238ra71.

20. PY Kuo, V Leshchenko, M Fazzari, T Gellen, J Iqbal, S Baumgartner-Wennerholm, L Nygren, F Zhang, W Zhang, K Suh, A Goy, D Yang, W Chan, B Kahl, A Verma, R Gascoyne, E Kimby, B Sander, B. H Ye, A Melnick, D Perumal, T He, S Parekh. High resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma. 2014. Oncogene. Mar 31;0. doi: 10.1038/onc.2014.44. [Epub

ahead of print.

21. S Walker, S Liu, M Xiang, M Nicolais, KHatzi, E Giannopoulou, OElemento, L Cerchietti, A Melnick, DA Frank. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. 2014. Oncogene. Mar 24. doi: 10.1038/onc.2014.61. [Epub ahead of print].

22. T Prebet, Z Sun, ME Figueroa, R Ketterling, A Melnick, P Greenberg, J Herman, M Juckett, MR Smith, L Malick, E Paietta, M Czader, J Gabrilove, H Erba, SD Gore, MS Tallman. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia Intergroup trial E1905. 2014. J Clinical Oncology. 32(12):1242-8.

23. B Bartholdy, M Christopelt, B Will, Y Mo, L Barreyro, Y Yu, T Bhagat, UC Okoye-Okafor, TI Todorova, JM Greally, RL Levine, A Melnick, A Verma, U Steidl. DNA cytosine methylation during commitment of human hematopoietic stem cells, and prognostic impact on overall survival in acute myeloid leukemia. 2014. J Clinical Investigation. 124(3):1158-67

24. N Chambwe, M Kormaksson, H Geng, S De, A Melnick, F Campagne, R Shaknovich. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. 2014. Blood. 123(11):1699-708.

25. JA Oyer, X Huang, Y Zheng, J Shim, T Ezponda, M Allegreta, CI Okot-Kotber, JP Patel, A Melnick, RL Levine, AA Ferrando, AD MacKerellJr, NL Kelleher, JD Licht, R Popovic. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. 2014. Leukemia. 28(1):198-201.

26. A Di Ruscio, AK Ebralidze, T Benoukraf, G Amabile, AL Gof, ME Figueroa, J Terragni, P Zhang, M Alberich-Jorda, LL De Figuerido Pontes, F D’Alo M Wu, A Melnick, S Pradham, G Leone, J Rinn, DG Tenen. DNMT1-interacting RNAs block gene specific DNA methylation. 2013. Nature. 503(7476):371-6.

27. LP Vu, F Perna, F Voza, ME Figueroa, P Tempst, H Erdjument-Bromage, T Deblasio, A Melnick, X Zhao, SD Nimer. PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. 2013. Cell Reports. 5(6):1625-38.

28. C Huang, H Geng, L Wang, I Boss, L Wang, A Melnick. Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. 2014. Blood.123(7):1012-20.

29. AY Lai, D Mav, R Shah, SA Grimm, D Phadke, K Hatzi, A Melnick, C Geigerman, SE Sobol, Dl Jaye, PA Wade. DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B cell activation. 2013. Genome Research. 23(12):2030-41.

30. C Lu, S Venneti, A Akalin, F Fang, PS Ward, RG DeMatteo, AM Intlekofer, C Chen, J Ye, JR Cross, R Khanin CE Mason, JH Healey, SW Lowe, GK Schwartz, A Melnick, and CB Thompson. Induction of sarcomas by mutant IDH2. 2013. Genes and Development. 27(18):1986-98.

31. Q Qiao, C Yang, C Zheng, L Fontan, L David, X yu, WC Bracken, M Garcia, A Melnick, EH Egelman, H Wu. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation induced filamentous assembly. 2013. Molecular Cell. 51(6):766-79. Cited by Faculty of 1000.

32. XJ Sun, Z Wang, L Wang, Y Jiang, N Kost, TD Soong, WY Chen, Z Tang, T Nakadai, O Elemento, W Fischle, A Melnick, DJ Patel, SD Nimer, RG Roeder. A stable transcription factor complex nucleated by dimerized AML1-ETO contributes to leukemogenesis and offers a therapeutic target. 2013. Nature. 500(7460):93-7.

33. K Hatzi, Y Jiang, F Garrett-Bakelman, E.G. Giannapolou, P Zumbo, K Kirouac, S Bhaskara, M Kormaksson, SW Hiebert, GG Privé, VJ Bardwell, O Elemento, A Melnick. A hybrid mechanism of action for BCL6 in B-cells defined by formation of functionally distinct complexes at enhancers and

promoters. 2013. Cell Reports. 4(3):578-88.

34. C Bertolo, S Roa, A Sagardoy, EF Robles, JI Martinez-Ferrandis, Z Saegert, A Orta, IS Lossos, S Amar, Y Natkunam, J Briones, A Melnick, R Malumbres, JA Martinez-Climent. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. 2013. British Journal of Hematology. 162(5):621-30.

35. T Clozel, SN Yang, M Kormaksson, R Shaknovich, R Elstrom, A Vasanthakumar, P Martin, M Leser, S Cheng, L Wang, W Tam, A Chadburn, L Godley, A Melnick*, L Cerchietti. Chemosensitization of Diffuse Large B-cell Lymphoma cells by demethylating nucleoside analogs. 2013. Cancer Discovery. 3(9):1002-19. * Corresponding author.

36. ME Figueroa, SC Chen, AK Andersson, LA Phillips, Y Li, J Sotzen, M Kundu, JR Downing, A Melnick*, C Mullighan. Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype. 2013. J Clin Investigation. 123(7):3099-111. * Corresponding Author.

37. U Nayar, P Lu, RL Goldstein, J Vider, G Ballon, A Rodina, T Taldone, H Erdjument-Bromage, M Chomet, R Blasberg, A Melnick, L Cerchietti, G Chiosis, L Wang, E Cesarman. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. 2013. Blood. 122(16):2837-47.

38. S Swaminathan, C Huang, H Geng, Z Chen, R Harvey, H Kang, C Ng, B Titz, C Hurtz, F Sadiyah, D Nowak, GB Thoennissen, V Rand, TRANSGENIC Graeber, HP Koeffler, WL Caroll, Cl Willman, AG Hall, K Igarashi, A Melnick, M Müschen. BACH2 mediates negative selection and p53 dependent tumor suppression at the pre-B cell receptor checkpoint. 2013. Nature Medicine. 19(8):1014-22.

39. J Ruan, C Wang, SN Yang, H Geng, JP Leonard, A Melnick, L Cerchietti, KA Hajjar. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. 2013. Blood. 121(26):5192-202.

40. W Béguelin, R Popovic, MR Teater, Y Jiang, KL Bunting, M Garcia, H Shen, SN Yang, L Wang, T Ezponda, E Martinez-Garcia, H Zhang, Y Zhang, SK Verma, M McCabe, HM Ott, GS Van Aller, RG Kruger, Y Liu, CF McHugh, DW Scott, YR Chung, N Kelleher, R Shaknovich, Cl Creasy, RD Gascoyne, KK Wong, LC Cerchietti, RL Levine, O Abdel-Wahab, JD Licht, O Elemento, A Melnick. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. 2013. Cancer Cell. 23(5):677-92. Cited by Faculty of 1000

41. A Sagardoy, JI Martinez-Ferrandis, S Roa, K Bunting, A Aznar, O Elemento, R Shaknovich, L Fontan, V Fresquet, I Perez-Roger, EF Robles, X Sagaert, A Melnick*, JA Martinez-Climent. Down regulation of FOXP1 is required during germinal center B-cell function. 2013. 121(21):4311-20. * Corresponding Author.

42. S Li, FE Garrett-Bakelman, A Akalin, P Zumbo, RL Levine, A Melnick, CE Mason. eDMR: An optimized algorithm for detecting and annotating regional differential methylation. 2013. BMC Bioinformatics. BMC Bioinformatics. 14 Suppl 5:S10.

43. B Will, To Vogler, B Bartholdy, F Garrett-Bakelman, J Mayer, A Pandolfi, TI Todorova, UC Okoye-Okafor, RF Stanley, TD Bhagat, A Verma, ME Figueroa, A Melnick, U Steidl. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. 2013. Nature Immunology. 14(5):437-45.

44. Z Lu, AG Tsai, T Akasaka, H Ohno, Y Jiang, A Melnick. H Greisman, MR Lieber. BCL6 Breakpoint Sequences indicate that IgH–BCL6 and non-Ig–BCL6 Rearrangements are AID-Dependent but Have Distinct Origins. 2013. Blood. 121(22):4551-4.

45. C Huang, K Hatzi, A Melnick. Cell-lineage specific biological functions of BCL6 in immunity and

inflammation are mediated through specific and distinct biochemical mechanisms. 2013. Nature Immunology. 14(4):380-8. Cited by the Faculty of 1000.

46. S Kanaan, R Sutphin, M Hall, L Goffman, W Fang, R Nolo, L Akers, R Hammitt, J McMurray, S Kornblau, A Melnick, ME Figueroa, P Zweidler-McKay. 2013. Journal of Experimental Medicine. 11;210(2):321-37.

47. J Oh, N Chambwe, S Andrews, G Judit, G Gleason, R Shaknovich, A Melnick, F Campagne, M Toth. Pattern and dynamics of CpG methylation during maternal programming of anxiety via the 5HT1A receptor. 2013. Translational Psychiatry. 3:e218. doi: 10.1038/tp.2012.130.

48. AC Wilkinson, A Ballabio, H Geng, P North, J Kerry, M Tapia, D Biswas, RG Roeder, CD Allis, A Melnick, M Brujin, T Milne. RUNX1 is a key target gene in MLL-AF4 leukemias and contributes to gene activation by interacting with the MLL-AF4 complex. 2013. Cell Reports. 3(1):116-27.

49. S De, R Shaknovich, M Riester, O Elemento, H Geng, M Kormaksson, Y Jiang, B Wollcock, N Johnson, JM Polo, RD Gascoyne, A Melnick*, F Michor. Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. 2013. PLoS Genetics. 10.1371/journal.pgen.1003137. * Corresponding author

50. AV Krivtov, ME Figueroa, AU Sinha, MC Stubbbs, Z Feng, PJ Valk, R Delwel, K Dohner, L Bullinger, AL Kung, A Melnick, SA Armstrong. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. 2013. Leukemia. 27(4):852-60.

51. PC Lin, YL Chiu, S Banerjee, P Alves, E Giannapolou, K Park, JM Mosquera, A Tewari, MB Gerstein, H Beltran, A Melnick, O Elemento, F Demichelis, MA Rubin. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. 2013. Cancer Research. 73(3):1232-1244.

52. M Park, E Lee, N Moskowitz, S Lee, J Lorenzo, C Huang, A Melnick, E Perdue, S Goldring, L Ivashkiv. Negative Regulation of Osteoclast Precursor Differentiation by CD11b and β2 Integrin-BCL6 Signaling. 2013. Journal of Bone and Mineral Research. 28(1):135-49.

53. P Ramezani-Rad, H Geng, Z Chen, LN Chan, C Hurtz, H Jumaa, A Melnick, E Paietta, WL Carroll, CL Willman, V Lefebvre, M Müschen. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. 2013. Blood. 121(1):148-55.

54. S Nischal, L Zhou, T Bhagat, B Will, Y Mo, M Suzuki, S Maqbool, A Pardanani, U Steidl, M McDevitt, J Maciejewski, J Spivak, A Melnick, J Greally, A Moliterno, A Verma. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. 2013. Cancer Res. 73(3):1076-85.

55. JM Polo, E Adersoon, RM Walsh, BA Schwartz, CM Nefzger, SM Lim, M Borkent, E Apostolou, S Aleal, J Cloutier, O Bar-Nur, S Cheloufi, M Stadtfeld, ME Figueroa, D Robinton, S Natesan, A Melnick, J Zhu, S Wamaswamy, K Hochedlinger. A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells. 2012. Cell. 151(7): 1617-1632.

56. L Fontan, C Yang, M Garcia, L Cerchietti, R Shaknovich, SN Yang, F Fang, F Glickman, RD Gascoyne, H Wu, A Melnick. MALT1 Small Molecule Inhibitors Specifically Suppress Activated B cell Subtype Diffuse Large B-cell Lymphomas in Vitro and in Vivo. 2012. Cancer Cell. 22(6):812-24. Cited by Faculty of 1000.

57. M Alberich-Jorda, B Wouters, M Balastik, C Shapiro-Koss, H Zhang, A DiRuscio, HS Radomska, A Ebralidze, G Amabilie, M Ye, J Zhang, I Lowers, R Avellino, A Melnick, M Figueroa, P Valk, R Delwel, D Tenen. C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. 2012. J Clin Investigation. 122(12):4490-504.

58. H Geng, S Brennan, TA Milne, WY Chen, Y Li, SM Kweon, L Zickl, S Shojaee, D Neuberg, C Huang, D Biswas, Y Xin, J Racevskis, R Ketterling, S Richards, S Luger, H Lazarus, MS Tallman, J

Rowe, M Litzow, ML Guzman, CD Allis, RG Roeder, M Müschen, E Paietta, O Elemento, A Melnick. Integrative epigenomic analysis adult B-acute lymphoblastic leukemia identifies biomarkers and therapeutic targets. 2012. Cancer Discovery. 2(11):1004-1023.

59. P Ouillette, J Li, R Shaknovich, A Melnick, K Shedden, SN Malek. 1. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. 2012. Genes Chromosomes Cancer. 51(12):1125-32.

60. L Busque, JP Patel, A Vasanthakumar, S Provost, Z Hamilou, L Mollica, J Li, A Viale, M Hassimi, N Socci, M Gonen, C Mason, A Melnick, LA Godley, C Brennan, O Abdel-Wahab, RL Levine. Recurrent Somatic TET2 Mutations in Elderly Individuals with Clonal Hematopoiesis. 2012. Nature Genetics. 51(12):1125-32.

61. A Akalin, M Kormaksson, S Li, FE Garrett-Bakelman, ME Figueroa, A Melnick, C Mason. methylKit: A comprehensive R package for the analysis of genome-wide DNA methylation profile. 2012. Genome Biology. 13(10):R87.

62. O Abdel Wahab, M Adii, L Saunders, J Gao, T Hricik, AH Shih, S Pandey, J Patel, F Perna, X Zhao, C Park, M Carroll, A Melnick, SD Nimer, JD Jaffe, I Aifantis, BE Bernstein, RL Levine. ASXL1 Mutations Promote Myeloid Transformation Through Loss of PRC2-Mediated Gene Repression. 2012. Cancer Cell. 22(2):180-93.

63. M Gonen, Z Sun, ME Figueroa, JP Patel, O Abdel-Wahab, J Racevskis, RP Ketterling, H Fernandez, JM Rowe, MS Tallman, A Melnick, RL Levine, E Paietta. CD25 expression improves risk classification in AML and provides prognostic insight independent of established biomarkers: ECOG phase III trial E1900. 2012. Blood. 120(11):2297-306.

64. M Kawahara, A Pandolfi, B Bartholdy, L Barreyro, B Will, M Roth, UC Okoye, T Todorova, ME Figueroa, A Melnick, CS Mitsiadis, and U Steidl, H2.0-Like Homeobox (Hlx) Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia. Cancer Cell, 2012. 22(2):194-208.

65. Y Jiang, D Soong, L. Wang, A Melnick*, O Elemento. Genome wide detection of genes targeted by Non-Ig somatic hypermutation in lymphoma. 2012. PLoS One, 7(7): e40332. doi:10.1371/journal.pone.0040332. * Corresponding author

66. M Sasaki, CB Knobbe, JC Munger, E Lind, D Brenner, A Brustle, IS Harris, R Holmes, J Haight, A You-Ten, D Wakeham, D Barber, M Figueroa, A Melnick, JC Zuniga-Plucker, TW Mak. 2012. Nature. 488(7413):656-9.

67. A Alkalin, FE Garrett-Bakelman, M Kormaksson, J Busuttil, L Zhang, I Khrebtukova, TA Mine, Y Hhuang, D Biswas, JL Hess, CD Allis, RG roeder, PJM Valk, B Lowenberg, R Delewel, HF Fernandez, E Paietta, MS Tallman, GP Schroth, CE Mason, A Melnick*, ME Figueroa. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in Acute Myeloid Leukemia. 2012. PLoS Genetics. 8(6):e1002781. * Corresponding author

68. M Kormaksson, J Booth, ME Figueroa, A Melnick. Integrative model based clustering of microarray methylation and expression data. 2012. Annals of Applied Statistics. 6(3):1327-1347.

69. E Cubedo, AJ Gentles, C Huang, Y Natkumam, S Bhatt, X Lu, I Romero-Camarero, A Freud, S Zhao, SK Plevritis,m JA Martinez Climent, I Sanchez Garcia, A Melnick, IS Lossos. Identification of LMO2 transcriptome and interactome in diffuse large B cell lymphoma. 2012. Blood. 119(23):5478-9.

70. DS Rickman, TD Soong, B Moss, JM Mosquera, S Terry, TY MacDonald, K Bunting, A Melnick, O Elemento, MA Rubin. Oncogene-mediated alterations in chromatin conformation. 2012. PNAS. 109(23):9083-8.

71. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B, Valk PJ, Delwel R. Mutant DNMT3A: a new marker of

poor prognosis in acute myeloid leukemia. 2012. Blood. 119(24):5824-31.

72. Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai LJ, Leblanc M, Diehl C, Cerchietti L, Miller YI, Witztum JL, Melnick A, Dent AL, Tangirala RK, Evans RM. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. 2012. Cell Metab. Apr 4;15(4):554-62.

73. J Patel, M Gonen, ME Figueroa, H Fernandez, Z Sun, J Racevskis, P Van Vlierberghe, I Dolgalev, S Thomas, O Aminova, K Huberman, J Cheng, A Viale, ND Socci, A Heguy, A Cherry, G Vance, RR Higgins, RP Ketterling, RE Gallagher, M Litzow, HM Lazarus, JM Rowe, S Luger, A Ferrando, E Paietta, M Tallman, A Melnick, O Abdel-Wahab, RL Levine. Prognostic and therapeutic relevance of integrated mutational profiling in AML. 2012. New England Journal of Medicine. 366(12):1079-89. Cited by the Faculty of 1000.

74. C Lu, PS Ward, GS Kapoor, D Rohle, O Abde-Wahab, C Edwards, R Khanin, ME Figueroa, A Melnick, KE Wellen, DM O’Rourke, SL Berger, TA Chan, RL Levine, IK Mellinghoff, CB Thompson. Impaired histone demethylation contributes to the cell differentiation arrest induced by cancer-associated isocitrate dehydrogenase mutation. 2012. Nature. 483(7390):474-8. Cited by Faculty of 1000.

75. D Pollyea, HE Kohrt, L gallegos, ME Figueroa, O Abdel-Wahab, B Zhang, S Battacharya, J Zehnder, M Liedtke, JR Gotlib, S Coutre, C Berube, A Melnick, RL Levine, BS Mitchell, BC Medeiros. Safety, Efficacy and Biological Predictors of Response to Azacytidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia. 2012. Leukemia. 26(5):893-901.

57. S Cheng, G Coffey, XH Zhang, R Shaknovich, Z Song, P Lu, A Pandey, A Melnick, U Sinha, YL Wang. SYK inhibition and response prediction in diffuse large B-cell lymphoma. 2011. Blood. 118(24):6342-52.

58. K Moulick, JH Ahn, L Cerchietti, K Beebe, P Smith-Jones, F Perna, K Hatzi, P Vu, D Zatorska, T Taldone, A Rodina, M Alpaugh, H Erdjument-Bromage, F Campagne, M Guzman, R Levine, E Chen, Y Ma, SS Gross, SM Larson, S Nimer, A Melnick*, L Neckers, G Chiosis. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. 2011. Nature Chem Biol. 7(11):818-26. * Corresponding author, Cited by the Faculty of 1000.

59. E Oricchio, G Nanjangud, AL Wolfe, JH Schatz, KJ Mavrakis, M Jiang, J Bruno, A Heguy, AB Olshen, ND Socci, J Teruya-Feldstein, F Weis-Garcia, W Tam, R Shaknovich, A Melnick, JP Himanen, RSK Chaganti, HG Wendel. A short form of the Eph-receptor A7 (EPHA7) has tumour suppressive activity in follicular lymphoma that can be restored for therapy. 2011. Cell. 147(3):554-64.

60. C Hurtz, C Duy, L Cerchietti, K Chatzi, E Park, L Klemm, Y Kim, S Herzog, H Jumaa, M Braig, M Kahn, A Melnick, M Muschen. BCL6 is required for leukemia initiation in chronic myeloid leukemia. 2011. J Exp Med. 208(11):2163-74.

61. Nahal, P Ramezani-Rad, M Mossner, C Duy, L Cerchietti, H Geng, H Jumaa, A Melnick, BH Ye, M Muschen. Pre-B-cell receptor mediated activation of BCL6 limits pre-B-cell proliferation through transcriptional repression of MYC. 2011. Blood. 118(15):4174-8.

62. R Shaknovich, L Cerchietti, M Kormaksson, S De, ME Figueroa, L Tsikitas, G Ballon, A Vasanthankumar, T Ekstrom, J Frank, F Michor, LA Godley, O Elemento, A Melnick. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. 2011. Blood. 118(13):3559-69.

63. L Wang, A Gural, F Perna, X Sun, X Zhao, MA Hateln, H Xu, G Huang, F Liu, H Xu, T Deblasio, S Menendez, F Voza, Y Jiang, J Zhang, A Melnick, B Roeder, SD Nimer. The leukemogenicity of AML1-ETO is dependent on site specific lysine acetylation. 2011. Science. 333(6043):765-9.

64. K Moran-Crusio, L Reavie, A Shih, O Abdel-Wahab, D Ndiaye-Lobry, C Lobry, M Figueroa, A Vasanthakumar, J Patel, X Zhao, F Perna, S PAndey, J Madzo, C Song, Q Dai, C He, S Ibrahim, M Beran, J Zavadil, S Nimer, A Melnick, LA Godley, I Aifaintis, RL Levine. Tet2 loss leads to increased hematopoietic stem cell self renewal and myeloid transformation. 2011. Cancer Cell. 20(1):11-24. Cited by the Faculty of 1000

65. L Zhou, J Opalinska, D Sohal, Y Mo, S Kambhampati, S Parmar, T Baghat, S Nischal, C Alencar, C Hueck, M Suzuki, R Thomas, E Friedman, L Cytrin, A Pellagati, J Boultwood, U Steidl, S Parekh, A Wickrema, Y Saunthararajah, V Yajnik, C Mcmahon, A Melnick, JM Greally, A Verma. Integrative genomic analysis reveals aberrant epigenetic and genetic marks in MDS peripheral blood leucocytes. 2011. J Biol Chem. 286(28):25211-23.

66. C Duy, L Cerchietti, S Swaminathan, L Klemm, S SHojaee, W Ci, M Braig, H Geng, WK Hoffman, HP Koeffler, JJ Yu, R Nahar, S Kweon, C Hurtz, L Henninghausen, J Groffen, N Heisterkamp, BH Ye, A Melnick, M Muschen. BCL6 enables Ph1 acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition. 2011. Nature. 473 (7347):384-388. Cited by the Faculty of 1000.

67. Cerchietti, C Damm-Welk, I Vater, W Klapper, L Harder, C Pott, A Reiter, R Seibert, A Melnick, W Woessman. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive diffuse large B-cell lymphomas. 2011. PLoS ONE Apr 8;6(4):e18436.

68. H Alvarez, J Opalinska, L Zhou, D Sohal, MJ Fazzari, Y Yu, C Montagna, EA Montgomery, M Canto, KB Dunbar, J Wang, JC Roa, Y Mo, T Bhagat, KH Ramesh, L Cannizzaro, RF Thompson, M Oda, S Meltzer, A Melnick, JM Greally, A Maitra, A Verma. Widespread hypomethylation occurs early during Barrett’s esophagus and synergizes with gene amplification during carcinogenesis. 2011. PLoS Genetics. Mar;7(3):e1001356.

69. P V Vlierberghe, J Patel, O Abdel-Wahab, C Lobry, CV Hedvat, M Balbin, C Nicolas, A Ramirez Payer, HF Fernandez, MS Tallman, EM Paietta, A Melnick, P Venderberghe, F Speleman, I Aifantis, J Cools, R Levine, A Ferrando. PHF6 mutations in adult acute myeloid leukemia. 2011. Leukemia. 25(1):130-4.

70. ME Figueroa, O Abdel-Wahab, C Lu, PS Ward, J Patel, A Shih, Y Li, N Baghwat, A Vasanthakumar, HF Fernandez, MS Tallman, Z Sun, K Wolniak, JK Peeters, W Liu, SE Choe, VR Fantin, E Paietta, B Lowenberg, JD Licht, LA Godley, R Delwel, PJ Valk, CB Thompson, RL Levine, A Melnick. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell. 18(6):553-67. Cited by Faculty of 1000.

71. L Cerchietti, K Hatzi, E Caldas-Lopes, SN Yang, ME Figueroa, R Shaknovich, K Bhallam, P Cole, G Chiosis, A Melnick. BCL6 repression of p300 provides a basis for rational combinatorial therapy in DLBCL. 2010. J Clin Investigation. 120(12):4569–4582.

72. S Lugthart, ME Figueroa, E Bindels, L Skrabanek, PJM Valk, Y Li, S Meyer, C Erpelinck-Verschueren, JM Greally, B Löwenberg, A Melnick*, R Delwel. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. 2011. Blood. 117(1):234-41. *Corresponding author.

73. I Velichutina, R Shaknovich, H Geng, N Johnson, RD Gacoyne, A Melnick, O Elemento. EZH2

Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis. 2010. Blood. 116(24):5247-5.

74. JM Polo, S Liu, ME Figueroa, W Kulalert, S Eminli, KY Tan, E Apostolou, M Stadtfeld, Y Li, S Natesan, A Wagers, A Melnick, T Evans, K Hochedlinger. Cell of origin influences molecular and functional properties of murine induced pluripotent stem cells 2010. Nature Biotechnology. 28(8):848-55. Cited by the Faculty of 1000

75. R Shaknovich, H Geng, N Johnson, L Tsikitas, L Cerchietti, J Greally, RD Gascoyne, O Elemento, A Melnick. DNA methylation signatures define molecular subtypes of Diffuse Large B Cell Lymphoma. 2010. Blood. 116(20):e81-9.

76. MM Murphy, AL Sarver, D Rice, K Chatzi, K Ye, A Melnick, L Heckert, D Zarkower, VJ Bardwell. Genome wide analysis of DNA binding and transcriptional regulation by the mammalian doublesex homolog DMRT1 in the juvenile testis. 2010. PNAS. 107(30):13360-5.

77. MY Shah, NY Barnes, A Vasanthakumar, ME Figueroa, A Kamp, C Hendrick, SE Volker, G Patel, KR Ostler, J Esposito-Cespedes, EM Davis, MM Le Beau, D Kuck, F Lyko, I Moskowitz, A Melnick, P Pytel, LA Godley. Transgenic mice expressing a truncated DNMT3B protein found in cancer cells display altered DNA methylation and disrupted embryonic development. 2010. Cancer Res. 70(14):5840-50.

78. RL Elstrom, P Martin, K Ostrow, A Chadburn, R Furman, J Ruan, T Shore, M Schuster, L Cerchiettie, A Melnick, M Coleman, JP Leonard. Response to second line therapy clearly defines curative potential of patients with recurrent diffuse large B cell lymphoma (DLBCL): Implications for development of novel therapeutic strategies. 2010. Clinical Lymphoma, Myeloma & Leukemia. 10(3):192-6.

79. V Leschenko, PY Kuo, R Shaknovich, DT Yang, T Gellen, Y Remache, M Weniger, S Rafiq, S Suh, A Goy, W Wilson, A Verma, N Muthusamy, B Kahl, J Byrd, A Wiestner, A Melnick, S Parekh. Genome wide DNA methylation analysis reveals novel targets for drug development in Mantle Cell Lymphoma. 2010. Blood. 116(7):1025-34. Plenary Paper.

80. C Duy, JJ Yu, JM Polo, L Klemm, L Cerchietti, S Herzog, A Melnick, BH Ye, M Muschen. BCL6 promotes pre-B cell survival during immunoglobulin light chain gene rearrangement. 2010. J Exp Med. 207(6):1209-21. Cited by Faculty of 1000 Biology.

81. ES Schafer, R Irizarry, S Negi, E McIntyre, D Small, ME Figueroa, A Melnick, P Brown. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. 2010. Blood. 115(23):4798-809.

82. R Shaknovich, ME Figueroa, A Melnick. HELP (HpaII tiny fragment enrichment by ligation mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. 2010. Methods in Molecular Biology. 632:191-201.

83. JN Winter, S Li, V Auroaroa, D Variakojis, B Nelson, M Krajewska, L Zhang, TM Habermann, RI Fisher, PJ Kurtin, WR Macon, M Chhanabhai, RE Felgar, ED His, LJ Medeiros, JK Weick, EA Weller, A Melnick, JC Reed, SJ Horning, RD Gsacoyne. P21 predicts clinical outcome in RCHOP but not CHOP treated patients with DLBCL. 2010. Clin Cancer Res. 16(8):2435-42

84. L Cerchietti, A Ghetu, X Zhu, GF Da Silva, S Zhing, JM Polo, M Matthews, C Fares, CH

Arrowsmith, A Coop, GG Privé, A Mackerell, A Melnick. A small molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. 2010. Cancer Cell. 17(4):400-11. Cited by Faculty of 1000 Medicine

85. ME Figueroa, S Lugthart, Y Li, C Erpelinck-Verschueren, X Deng, PJ Christos, E Schifano, J Booth, W van Putten, L Skrabanek, F Campagne, M Mazumdar, JM Greally, PJM Valk, B Löwenberg, R Delwel, A Melnick. Epigenetic signatures identify New Clinically Relevant Subtypes in Acute Myeloid Leukemia. 2010. Cancer Cell, 17(1):13-27. Cited by Faculty of 1000 Medicine and Faculty of 1000 Biology.

86. P Juszczynski, L Cheng, E O’Donnel, JM Polo, SM Ranuncolo, R Dalla-Favera, A Melnick, MA Shipp. BCL6 regulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. 2009. Blood. 114(26):5315-21

87. S Hammerich-Hille, A Tsimelzon, BA Kaiparettu, C Creighton, S Jing, JM Polo, A Melnick, R Mayer, S Oesterreich. SAF1B mediates repression of immune regulators and apoptotic genes in breast cancer cells. 2009. J Biol Chem. 285(6):3608-16.

88. L Cerchietti, EC Lopes, S Nin, K Hatzi, G Chiosis, A Melnick. A purine scaffold Hsp90 inhibitor destabilizes BCL6 and has specific anti-tumor activity in BCL6 dependent DLBCLs in vitro and in vivo. 2009. Nature Medicine. 15(12):1369-76.

89. ME Figueroa, L Skrabanek, Y Li, JD Licht, H Carraway, SD Gore, A Melnick. Distinct patterns and abundance of aberrant DNA methylation in MDS and de novo AML. 2009. Blood. 114(16):3448-58. Cited by Faculty of 1000 Medicine.

90. M Oda, JL Glass, RF Thompson, Y Mo, E Olivier, ME Figueroa, RR Selzer, TA Richmond, X Zhang, L Dannenberg, RD Green, A Melnick E Hatchwell, EE Bouhassira, A Verma, M Suzuki, JM Greally. Simultaneous high resolution genome wide cytosine methylation and copy number analysis applied to limited cell numbers. 2009. Nucleic Acids Research. 37(12):3829-39.

91. EC Lopes, L Cerchietti, A Robles, L Varticovski, A Melnick, G Chiosis. In vivo antitumor efficacy of purine-scaffold Hsp90 inhibitors in basal-like breast cancer (BLBC). 2009. PNAS. 106(20):8368-73

92. W Ci, JM Polo, L Cerchietti, R Shaknovich, L Wang, SN Yang, K Ye, P Farinha, D Horsman, RD Gascoyne, O Elemento, A Melnick. The BCL6 transcriptional program features repression of multiple oncogenes in primary B-cells and is deregulated in DLBCL. 2009. Blood. 113(22):5536-48.

93. ME Figueroa, B Wouters, M Reimers, J Glass, Y Li, M Fazzari, B Lowenberg, P Valk, JM Greally, A Melnick*, R Delwel, Integrated epigenetic analyses delineates a biologically distinct form of acute myeloid leukemia with T-cell lineage infidelity. 2009. Blood. 113(12):2795-804. *Corresponding author.

94. ME Figueroa, A Melnick and JM Greally. Genome-Wide Determination of DNA Methylation by Hpa II Tiny Fragment Enrichment by Ligation-Mediated PCR (HELP) for the Study of Acute Leukemias. 2009. Methods in Molecular Biology. 538:1-13.

95. P Martin, A Chadburn, P Christos, K Weil, RR Furman, J Ruan, R Elstrom, R Niesvizky, S Ely, M Di Liberto, A Melnick, DM Knowles, S Chen-Kiang, M Coleman, JP Leonard. Outcome of Deferred

Initial Therapy in Mantle Cell Lymphoma. 2009. JCO. 27(8):1209-13. Cited by Faculty of 1000 Medicine.

96. A Laurenzana, L Petruccelli, F Pettersson, ME Figueroa, A Melnick, AS Baldwin, F Paoletti and WH Miller Jr. Inhibition of DNA methyltransferase activates TNFα -induced monocytic differentiation in acute myeloid leukemia cells. 2009. Cancer Research. 69(1):55-64.

97. L Cerchietti, SN Yang, R Shaknovich, K Hatzi, JM. Polo, A Chadburn, SF Dowdy and A Melnick. A peptidomimetic inhibitor of BCL6 with potent anti-lymphoma effects in vitro and in vivo. 2009. Blood. 113(15):3397-405. Plenary Paper.

98. EC Lopes, ME Figueroa, A Mazur, FG Meng, PW Laird, N Schreiber-Agus, E Prokhortchouk, A Melnick. Kaiso is required for DNA methylation-dependent silencing of tumor suppressor genes in colon cancer. 2008. Cancer Research. 68(18):7258-63

99. D Sohal, A Yeatts, K ye, A Pellagati, L Zhou, P Pahanish, Y mo, T Bhagat, J Mariadason, J Boultwood, A Melnick, JM Greally, A Verma. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. 2008. PLoS ONE. 3(8):e2965.

100. AW Wilson, D Byun, S Nasser, L Murray, K Ayyanar, D Arango, ME Figueroa, A Melnick, GD

Kao, LH Augenlicht, JM Mariadason. HDAC4 promotes growth of colon cancer cells via repression of p21. 2008. Mol Biol Cell. 19(10):4062-75.

101. SM Ranuncolo, J Dierov, F. Rassool, M. Carroll, A Melnick. BCL6 expression attenuates DNA damage sensing and triggers oncogenic cellular stress and senescence through a p53 dependent pathway. 2008. J Biol Chem. 283(33):22565-72

102. L. Cerchietti, JM. Polo, GF. Da Silva, P. Farinha, RD Gascoyne, SF Dowdy, A Melnick. Sequential transcription factor targeting for diffuse large B-cell lymphomas. 2008. Cancer Research. 68(9):3361-9

103. JM Polo, W Ci, JD Licht, A Melnick. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B-cells. 2008. Blood. 112(3):644-51.

104. ME Figueroa, M Reimers, RF Thompson, K Ye, Y Li, RR Selzer, J Fridiriksson, E Paietta, P Wiernik, R Green, JM Greally, A Melnick. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS ONE. 2008 Mar 26;3(3):e1882. Cited by Faculty of 1000 Biology.

105. LM Mendez, JM Polo, M Krupski, J Yu, A Melnick, H Ye. CtBP is a novel and essential corepressor for BCL6 autoregulation. 2008. Mol Cell Biol. Apr;28(7):2175-86.

106. SM Ranuncolo, JM Polo and A. Melnick. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. 2008. Blood Cells Mol Dis. Jul-Aug;41(1):95-9.

107. A Ghetu, C. Corcoran, L. Cerchietti, V. Bardwell, A Melnick, and GG. Privé. Structure of a BCoR corepressor peptide in complex with the BCL6 BTB domain dimer. 2008. Molecular Cell. 29 (3) pp:384-391.

108. S Parekh, JM Polo, R Shaknovich, P Juszczynski, P. Lev, SM Ranuncolo, Y Yin, U Klein, G. Cattoretti, R Dalla Favera, MA Shipp, A Melnick. BCL6 programs lymphoma cells for survival and

differentiation through distinct biochemical mechanisms. 2007. Blood. 110(6)pp:2067-74. Cited by Faculty of 1000 Medicine

109. SM Ranuncolo, JM. Polo, J. Dierov, H. Jin, R. Shaknovich, C. Montagna, M. Carroll, A. Melnick. BCL6 mediates the germinal center B-cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. 2007. Nature Immunology. 8 (7) pp:705-14. Cited by Faculty of 1000 Biology.

110. JL Glass, RF. Thompson, B. Khulan, ME. Figueroa, E. Olivier, G. Van Zant, EE. Bouhassira, A. Melnick, A Golden, MJ. Fazzari, JM. Greally. CG dinucleotide clustering is a species specific, emergent property of the genome. 2007. Nucleic Acids Research. 35(20):6798-807

111. JM Polo, P. Juszczynski, S. Monti, L. Cerchietti, K. Ye, M. Shipp, A. Melnick. A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of DLBCL. 2007. Proceedings of the National Academy of Sciences. 104 (9) pp:3207-3212.

112. B Khulan, K. Ye, E. Stasiek, M. Figueroa, E. Hatchwell, R. Selzer, T. Richmond, R. Green, A. Melnick, JM. Greally. Genome-wide comparative isoschizomer profiling of cytosine methylation. 2006. Genome Research. 16 (8) pp:1046-55.

113. A Prokhortchouk, O. Sansom, J. Selfridge, F. Meng, A Melnick, E. Prokhortchouk, A. Clarke, A. Bird. Kaiso-deficient mice show resistance to intestinal cancer. 2006. Mol Cell Biol. 26 (1) pp:199-208.

114. JM. Polo, T Delloso, SM Ranuncolo, D Beck, CL Kiang, GG. Prive, JD. Licht, A Melnick. Specific blockade of BTB domain corepressor binding reveals transcriptional and oncogenic functions of the Bcl-6 oncoprotein. 2004. Nature Medicine. 10 (12) pp: 1329-1335. Cited by Faculty of 1000 Biology.

115. N Chevalier, C. Corcoran, G. Carlile, V. Bardwell, JD. Licht and A Melnick. ETO is a Co-Repressor for Bcl-6 in Both Normal and Malignant B-Lymphocytes. 2004. Blood. 103 (4) pp: 1454-1463.

116. S Takahashi, M. McConnell, H. Harigae, M. Kaku, T. Sasaki, A. Melnick, JD. Licht. Internal Tandem Duplication of Flt3 Inhibits the Function of Transcriptional Repressors by Blocking Interactions with SMRT. 2004. Blood. 103 (12) pp:4650-4658.

117. KF Ahmad, A. Melnick, S. Lax, D. Bouchard, J. Liu, C. Kiang, S. Mayer, JD. Licht, and GG. Privé.. Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. 2003. Molecular Cell. 12 (6) pp: 1551-1564.

118. RH Walker, S. Morgello, B Davidoff-Feldman, A. Melnick, MJ. Walsh, P. Shashidharan, MF. Brin. Autosomal Dominantly-inherited chorea-acanthocytosis with intranuclear neuronal inclusions; report of a family. 2002. Neurology. 58 (7) pp: 1031-1037

119. A Melnick, G. Carlile, F. Ahmad, G. Prive and JD. Licht. Critical Residues Within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors. 2002. Mol Cell Biol.22 (6): 1804-1818

120. A Melnick, G. Carlile, A. Polinger, S.W. Hiebert and J.D. Licht The AML-1/ETO Fusion Protein Dominantly Inhibits the Transcriptional Repressor Effects of PLZF and Other Co-Repressor Proteins. 2000. Blood. 96 (11): 3939-3947

121. A Melnick; K. Ahmed, S. Arai; A. Polinger; H. Ball, K. Borden, G. Prive, JD. Licht. In Depth

Mutational Analysis of the PLZF BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. 2000. Mol Cell Biol. 20 (17): 6560-6567.

122. A Melnick, J Westendorf, A. Polinger, G. Carlile, S. Arai, B. Lutterbach, SW Hiebert and JD Licht. The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. 2000. Mol Cell Biol. 20 (6): 2075-2086.

123. HJ. Ball, A Melnick, R. Shaknovich, RA Kohanski, JD. Licht. The Promyelocytic Leukemia Zinc Finger (PLZF) Protein Binds DNA in a High Molecular Weight Complex Associated with Cdc2 Kinase. 1999. Nucleic Acids Research. 27 (20):4106-4113.

124. ME. Hoatlin, Y. Zhi, H. Ball, K. Silvey, A. Melnick, S. Stone. S. Arai, N. Hawe, A. Zelent, JD. Licht. A Novel BTB/POZ Transcriptional Repressor Protein Interacts with the Fanconi Anemia Group C Protein and PLZF. 1999. Blood. 94 (11): 3737-3747.

125. A Melnick; S. Fruchtman; A. Zelent, L. Isola; M. Liu; Q. Huang; MJ. Calasanz; A. Fernandez; JD. Licht; V. Najfeld. Identification of Novel Chromosomal Rearrangements in Acute Myelogenous Leukemia Involving Loci on Chromosome 2p23, 15q22 and 17q21. 1999. Leukemia. 13: 1534-1538.

126. R Shaknovich, P. Yeyati , H. Ball, A. Melnick, C. Lempert, S. Waxman, JD. Licht. The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. 1998. Mol Cell Biol. 18:5533-45.

127. JD Licht, R. Shaknovich, A. Melnick, MA. English, JY.Li, JC. Reddy, S. Dong, SJ. Chen, A. Zelent, S. Waxman. Reduced and Altered DNA-Binding And Transcriptional Properties Of The

PLZF-Retinoic Acid Receptor- Chimera Generated In t(11;17)-Associated Acute Promyelocytic Leukemia. Oncogene 12:323-336, 1996.

2. Peer reviewed reviews and book chapters 1. Y Jiang and A Melnick. Epigenetic basis of diffuse large B-cell lymphoma. 2015. Seminars in

Hematology. In Press.

1. K Hatzi, A Melnick. Breaking bad in the germinal center: the role of BCL6 in lymphomagenesis. 2014. Trends in Molecular Medicine. 20(6):343-352.

2. L Fontan, A Melnick. Molecular Pathways: Targeting MALT1 paracaspase activity in lymphomas. 2013. Clinical Cancer Research. 19(24):6662-8.

3. F Garrett-Bakelman, A Melnick. Therapeutic reprogramming of oncogenic metabolic programs by IDH enzyme small molecule inhibitors. 2013. Cell Research. 23(8):975-7.

4. L Cerchietti, A Melnick. Targeting Bcl-6 in diffuse large B-cell lymphoma: what does this mean for future treatment? 2013. Expert Review of Hematology. 6(4):343-5.

5. L Fontan, A Melnick. Discovering what makes STAT signaling TYK in T-ALL. 2013. Cancer Discovery. 3(5):494-6.

6. K Bunting, A Melnick. New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. 2013. Current Opinion in Immunology. 25(3):339-46.

7. V Santini, A Melnick, JP Maciejewski, E Duprez, C Nervi, L Cocco, Kg Ford, G Mufti.

Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. 2013. Critical Reviews in Oncology/Hematology. Jul 6. doi:pii: S1040-8428(13)00124-8.

8. L Fontan, A Melnick. Therapeutic targeting of MALT1 for B-cell lymphomas and beyond. 2013. Oncotarget. 3(12):1493-4

9. A Melnick. Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2. 2012. Cancer Cell. 22(5):569-70.

10. R Shaknovich, A Melnick. Epigenetic basis of B-cell lymphomas. 2011. Current Opinion in Hematology. May 13. 18(4):293-9.

11. A Melnick. Epigenetics in AML. Best Practice and Research in Clinical Hematology. 2010. Dec;23(4):463-8.

12. MS Cairo, CT Jordan, CC Maley, C Chao, A Melnick, SA Armstrong, W Shlomchik, J Molldrem, S Ferrone, B Tycko, C Mackall, L Zitvogel, MR Bishop, SA Giralt, CH June. NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse Following Allogeneic Stem Cell Transplantation Unrelated to Graft Versus Tumor Effects: State of the Science. Biol Blood Marrow Transplant. 2010 16(6):709-28.

13. A Melnick. Transitioning from fellowship to a physician scientist career track. 2008. Hematology Am Soc Hematol Educ Program. 2008:16-22.

14. A Zelent, K Petrie, M Chornet, A Melnick, S Waxman, S Gore. De-repression in the Desert: The Third Workshop on Clinical Translation of Epigenetics in Cancer. 2008. Cancer Research. 68 (13): 4967-4970

15. W Ci, JM Polo, A Melnick. B-Cell Lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. 2008. Current Opinion in Hematology. 15(4):381-90

16. S Parekh, GG Privé, A Melnick. Therapeutic targeting of BCL6 in diffuse large B-cell lymphomas. 2008. Leukemia and Lymphoma. 49(5):874-82

17. A Melnick. Targeting aggressive B-cell lymphomas with cell penetrating peptides. 2007. Biochem Soc transactions. 35(Pt 4) pp:802-6.

18. A Melnick. Targeting APL fusion proteins by peptide interference. 2007. Current Topics in Microbiology and Immunology. 313 pp:221-243.

19. GG Privé, A. Melnick. Specific peptides for the therapeutic targeting of oncogenes. 2006. Current Opinions in Genetics and Development. 16 (1) pp:71-77.

20. A Melnick, K. Adelson, JD. Licht. The Theoretical Basis of Transcriptional Therapy of Cancer: Can it be put into practice?. 2005. Journal of Clinical Oncology. 23 (17) pp: 3957-3970.

21. A Melnick. Predicting the Effect of Transcription Therapy in Hematologic Malignancies. 2005. Leukemia. 2005. Leukemia. 19 (7) pp: 1109-1117.

22. A Melnick. Reprogramming Specific Gene Expression Pathways in B-Cell Lymphomas. 2005. Cell Cycle. 4 (2) pp:239-241.

23. GG Prive. A. Melnick, J.D. Licht. The BTB/POZ family of Zinc Finger Transcription Factors. In: Zinc Finger Proteins: from Atomic Contact to Cellular Function. Edited by Shiro Iuchi and Natalie Kuldell. 2004. Landes Biosciences. ISBN: 0-306-48229-0

24. A Sirulnik, A. Melnick, A. Zelent, JD. Licht. Molecular Pathogenesis of Acute Promyelocytic Leukemia and APL Variants. 2003. Baillares Best Pract Res Clin Haematol, 16 (3) pp:387-408.

25. A Melnick. Spotlight on Acute Promyelocytic Leukemia: Challenges and Controversies. 2002. Leukemia. 16 (10) pp: 1893-1895

26. A Melnick and JD. Licht. Histone Deacetylases as Therapeutic Targets in Hematologic Malignancies. 2002. Curr Opin Hematol. 9 (4) pp: 322-332

27. A Melnick and J.D. Licht. The Role of RAR And Its Fusion Partners In Acute Promyelocytic Leukemia. In: Transcription Factors. Normal and Malignant Development of Blood Cells. Edited by Jonathan Licht and Katya Ravid. 2001. Wiley.& Sons. ISBN: 0-471-35054-0

28. A Zelent, F. Guidez, A. Melnick, S. Waxman, JD. Licht. Translocations of the RAR gene in

Acute Promyelocytic Leukemia. 2001. Oncogene. 20 (49): 7186-7203

29. A Melnick and JD. Licht. Deconstructing A Disease: RAR, Its Fusion Partners and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia. 1999. Blood. 93 (10):3167-3215

M. INVITED SPEAKER: 2015: Invited speaker, LLS symposium on epigenetics, Orlando, Fl 2015: Invited speaker, International Symposium Takamatsu Cancer Res Fund, Tokyo, Japan 2015: Invited speaker, EHA meeting on Leukemia, Budapest, Hungary 2015: Invited speaker, FASEB meeting on Hematologic Malignancies, Saxton River, VT 2015: Invited Speaker, 13th ICML Intl Conf on Malignant Lymphoma, Lugano, Switzerland 2015: Invited Speaker, University of Nebraska, Omaha, NE 2015: Keynote Speaker, Holden Comprehensive Cancer Center Symposium, Iowa City, IA 2015: Invited Speaker, Stem Cells and Cancer, Cell Press Symposium,NY, NY 2015: Invited Speaker, AACR meeting on Cancer Epigenetics 2015: Invited Speaker, AACR meeting on Brain Cancer 2015: Invited Speaker, Scripps Institute, La Jolla, CA 2015: Invited Speaker, AACR Annual Meeting, Philadelphia, PA 2015: Invited Speaker, 13th International Conference on Lymphomas, Lugano, Switzerland 2015: Gordon Conference on Cancer Genetics and Epigenetics, Il Ciocco, Tuscany, Italy 2015: US-Japan Malignant Hematopoiesis Meeting. Hawaii, HI 2015: NCI Genome Integrity Seminar Series. National Cancer Institute. Bethesda, MD. 2015: Cincinnati Children's Hospital Research Seminar, Cincinnati, OH 2015: Epigenetic therapy meeting. Saint Augustine, FL 2014: Tsinghua University Research Seminars, Jiaxing, China 2014: Cancer Research Symposium, Erasmus Medical Center, Rotterdam, Netherlands 2014: Japanese Society of Immunology, Kyoto, Japan 2014: Cancer Center Seminar, UCSF, San Francisco, CA 2014: University of Tokyo, Tokyo, Japan

2014: Janssen Pharmaceuticals, Beerse, Belgium 2014: Janssen Educiational Symposium, Weill Cornell, NYC 2014: Eli Lilly Pharmaceuticals, Indianapolis, IN 2014: Epizyme Pharmaceuticals, Boston, MA 2014: International Bioconductor Genomics Meeting, Ribeirao Preto, Brazil 2014: Brazilian Genetics Society Annual Meeting, Guaruja, Brazil 2014: Epigenetics Symposium, University of Miami, Miami, FL 2014: AACR meeting on Hematologic Malignancies, Philadelphia, PA 2014: Argentine Society of Hematology, Buenos Aires, Argentina 2014: ASH meeting on Lymphoma Biology, Colorado Springs, CO 2014: Gordon Conference on Proteases, Il Ciocco, Tuscany, Italy 2014: Celgene Hematologic Malignancies Conference, Munich, Germany 2014: European Hematology Association Annual Meeting, Milan, Italy 2014: Myeloid Development Conference, Cincinnati, OH 2014: ABCAM Epigenetics Symposium, Boston, MA 2014: AACR Annual Meeting, San Diego, CA 2014: Keystone meeting on Chromatin, Obertsdorf, Germany 2014: Keynote Speaker, Molecular Medicine Course, Erasmus University, Rotterdam 2014 Keynote Speaker, Molecular Medicine Symposium, Erasmus University, Rotterdam 2014: Grand Rounds, Daniel den Hoed Cancer Hospital, Rotterdam, Netherlands 2014: Grand Rounds, Memorial Sloan Kettering Cancer Institute 2014: International Congress on Hematologic Malignancies, New York, NY 2014: Celgene Research Meeting, San Francisco, CA 2014: Sylvester Cancer Center Distinguished Lecture Series, U Miami, Miami Florida. 2014: Cancer Center Seminar, Fels Institute, Temple University, Philadelphia, PA 2014: Pathology Department Research Seminar, U Michigan, Ann Arbor, MI 2013: Cancer Center Seminar, University of Pennsylvania. 2013: Cancer Center Seminar, Penn State Hershey Cancer Center, Hershey, PA 2013: Invited Speaker, Lymphoma and Myeloma Symposium, New York, NY 2013: PQG Symposium, Harvard University, Boston, MA 2013: Interurban Medical Conference, MSKCC, New York, NY 2013: Research Seminar, Dana Farber Cancer Center, Boston, MA 2013: Epigenomics Symposium, IRIC/University of Montreal, Canada. 2013: Epigenetics Symposium, Keynote Speaker. Duke University, NC 2013: Swerling Symposium, Dana Farber Cancer Institute, Boston, MA 2013: Research Seminar, Janssen Pharmaceuticals, Sunny Bridge, PA 2013: Leukemia Grand Rounds. MD Anderson Cancer Center, Houston, TX 2013: Institute for Biology and Experimental Medicine (IBYME). Buenos Aires, Argentina. 2013: Cancer Center Seminar. Roffo Cancer Research Institute of the University of Buenos Aires,

Argentina. 2013: AACR meeting on Chromatin and Epigenetics, Atlanta, GA 2013: FASEB meeting on Hematologic Malignancies, Saxtons River, VT 2013: Education Session, 2013 AACR annual meeting, Washington DC 2013: Leukemia scientific session, 2013 AACR Annual Meeting, Washington DC 2013: Leukemia Molecular Workshop, Munich, Germany 2012: Chemotherapy Symposium, New York, NY. 2012: Lymphoma and Myeloma meeting, New York, NY. 2012: 2012 New York Symposium in Epigenomics. Albert Einstein College of Medicine, Bronx, NY 2012: Plenary Session Invited Speaker, 41st Autumn Immunology Conference, Chicago, IL. 2012: Invited Speaker, Cold Spring Harbor Asia/The 13th International Conference on

Differentiation Therapy: Differentiation Therapy and Advances in Cancer, Suzhou, China.

2012: Invited Speaker, IDIBELL Cancer Conference (ICC) on Epigenetics in Lymphocyte Biology and Disease, Barcelona, Spain.

2012: Invited Speaker, Modern Trends in Human Leukemia and Cancer, Wilsede, Germany. 2012: Keynote Speaker, Centre de Recherche en Cancerologie de Marseille, Marseille, France. 2012: Session Chair and Speaker, Cold Spring Harbor Symposium Mechanisms & Models of

Cancer, Cold Spring Harbor, NY 2012: Cancer Center Seminar, University of Pennsylvania 2012: Keystone Meeting on Biological Methylation. Snowmass, CO. 2012: Research Seminar, Bristol Meyers Squibb. Princeton, NJ 2012: Cancer Molecular Therapeutics Meeting. Princeton, NJ 2012: Keynote Speaker, International Society for Experimental Hematology (ISEH), Amsterdam,

Holland. 2012: Keynote Speaker. Annual Meeting of the Dutch Hematology Association, Amsterdam,

Holland. 2012: Research Seminar. Erasmus Medical College, Rotterdam, Holland. 2012: Keynote Speaker, European Hematology Association Annual Meeting, Amsterdam, Holland. 2012: Meet The Expert, European Hematology Association Annual Meeting, Amsterdam, Holland. 2012: Leukemia Research Symposium, U Chicago, Chicago, IL. 2012: HICCC Cancer Center Annual Symposium, Columbia U, New York, NY. 2012: Cancer Center Seminar, Massachusetts General Hospital, Boston, MA. 2012: NCI Workshop on Myeloid Development. Cincinnati, Oh. 2012: Symposium on Epigenetics and Cancer, Ontario Cancer Institute, Toronto, Canada 2012: Keynote Speaker, New Directions in Leukemia Research, Queensland, Australia 2012: Research Seminar, University of Adelaide, Adelaide, Australia 2012: Research Seminar, Monash Institute, Melbourne, Australia 2012: FASEB Meeting on Biological Methylation. Carefree, AZ. 2012: Epigenetics in Lymphocyte Biology and Disease. Barcelona, Spain. 2012: Agios Pharmaceuticals. Boston, MA. 2011: Meet-the-Expert. American Society of Hematology Annual Meeting, San Diego, CA. 2011: Scientific Symposium. American Society of Hematology Annual Meeting, San Diego, CA. 2011: Lymphoma and Myeloma meeting, New York, NY. 2011: Astra Zeneca Seminar, Waltham, MA. 2011: Epigenetics in Cancer Symposium, U Pennsylvania, Philadelphia, PA. 2011: Cancer Center Seminar, New York University, NY 2011: Leukemia and Lymphoma Society Translational Research Meeting, New York, NY. 2011: NHLBI Workshop on Myelodysplasia, Bethesda, MD. 2011: Forbeck Symposium on Epigenetics. Hilton Head, SC. 2011: Symposium on Systems Biology of Diversity in Cancer, MSKCC, New York, NY. 2011: NCI Translational Science Meeting 2011, Bethesda, MD. 2011: International Symposium on Hematologic Malignancies. Pamplona, Spain. 2011: ENZON Pharmaceuticals Research Seminar, Piscataway, NJ. 2011: European Hematology Association Conference on Molecular Basis of Leukemia. Nice,

France. 2011: Epizyme. Research Seminar. Cambridge MA. 2011: “Hinterzartener Kreis for Cancer Research, From Cell Biology to Targeted Therapy” German

Research Foundation Think Tank. Lake Como, Italy 2011: Education Program, ASCO 47th Annual Meeting, Chicago, IL 2011: Keystone Symposium on New Insights into Normal versus Dysregulated B Cell Function,

Whistler, British Columbia, Canada 2011: FASEB meeting on Hematologic Malignancies, Saxtons River, VT 2011: European Epigenomics Consortium, Athens, Greece 2011: MD Anderson Cancer Center Grant Rounds, Houston, TX

2011: UCSF Cancer Center Grand Rounds, San Francisco, CA 2011: LIneberger Cancer Center Grand Rounds. University of North Carolina, Chapel Hill, NC. 2011: Clinical Translation of Epigenetics in Cancer Therapy Meeting, San Diego, CA 2011: Mount Sinai School of Medicine Cancer Center Grand Rounds, New York, NY 2010: Glaxo Smith Kline, Research Seminar. Philadelphia, PA. 2010: AACR Cancer Prevention Research Conference, Session Leader and Speaker, Philadelphia,

PA 2010: American Society for Cell Biology Annual Meeting, Philadelphia, PA 2010: NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After

Allogeneic Hematopoietic Stem Cell Transplantation, Bethesda, MD. 2010: Lymphoma and Myeloma 2010, New York, NY 2010: MDS epigenetics and immunomodulation meeting, Florence Italy. 2010: Hematology/Oncology Grand Rounds, University of Michigan Medical Center, Ann Arbor, MI. 2010: 8th International Workshop on Non-Hodgkin’s Lymphoma, New York, NY 2010: Cancer Center Grand rounds, USC, Los Angeles, CA 2010: Acute Leukemia Forum, San Francisco, CA 2010: Burke Institute, White Plains, NY 2010: CALGB meeting guest speaker 2010: 7th International Chicago Lymphoma Symposium 2010: National Cancer Institute – Physical Science in Oncology Center Symposium, VA. 2010: 12th International Conference on Malignancies in AIDS, Bethesda, MD 2010: 2010 Mantle Cell Consortium, Atlanta, GA 2010: European Hematology Association Annual Meeting, Barcelona, Spain. 2010: University of Vancouver Research Seminar, Vancouver, Canada 2010: British Columbia Cancer Agency, Grand Rounds, Vancouver, Canada 2010: NHLBI Research Seminar, Bethesda, MD 2010: Vanderbilt University Research Seminar, Nashville, TN 2010: Yale University Hematology Research Seminar, New Haven, CT 2009: 2009 Workshop on Myeloid Development, American Society of Hematology Annual Meeting.

New Orleans, LA. 2009: Argentine Society of Hematology Annual Meeting, Mar Del Plata, Argentina 2009: NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After

Allogeneic Hematopoietic Stem Cell Transplantation, Bethesda, MD 2009: Follicular Lymphoma Symposium, Chicago, IL 2009: Medicine Grand Rounds, Long Island Jewish Medical Center, Queens, NY 2009: Hematology Grant Rounds, Montefiore Medical Center, Bronx, NY 2009: ECOG group meeting, Philadelphia, PA 2009: Department of Medicine Grand Rounds, Weill Cornell Medical College, NY 2009: Erasmus Medical Center Research Center, Rotterdam, Netherlands 2009: GELA group meeting, Deauville, France 2009: Research Seminar, Oregon Health Science University, Portland, OR 2009: Association of Biomolecular Resource Facilities, Memphis, TN 2009: “Frontiers in Oncology” Special Seminar, University of Maryland, Baltimore, MD 2009: Eighth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and

Leukemia. Annapolis, MD. 2009: American Association for Cancer Research National Meeting. Invited Speaker. Denver, CO. 2009: Clinical Translation of Epigenetics in Cancer Therapy Meeting. Coral Gables, FL. 2008: Annual Meeting of the American Society of Hematology. Subcommittee on Myeloid neoplasia

Scientific Session. San Francisco, CA. 2008: Annual Meeting of the American Society of Hematology. Education Session on Career

Development. San Francisco, CA. 2008: Biochemistry Seminar. Weill Cornell Medical College. New York, NY.

2008: 2008 Workshop on Myeloid Development, American Society of Hematology Annual Meeting. San Francisco, CA.

2008: Research Seminar, Department of Biomedical Sciences, Cornell University, Ithaca, NY. 2008: Research Seminar, Department of Pharmacology, Weill Cornell Medical College, New York,

NY 2008: Lymphoma Workshop. CALGB Annual Meeting. Chicago, IL. 2008: Guest Speaker. Stohlman Symposium of the Leukemia and Lymphoma Society. Kansas

City, MO. 2008: National Cancer Institute (NCI) Hematopoietic Malignancies: Modeling, Biology and Therapy

Workshop. Harvard University School of Medicine, Boston, MA. 2008: Research Seminar. University of Chicago Cancer Center. Chicago, IL. 2008: American Association for Cancer Research National Meeting. Invited Speaker, San Diego,

CA. 2008: American Society of Hematology Workshop on Myelodysplasia. Washington DC. 2008: Joint Seminar Series of the Joseph Stokes Jr. Normal and Malignant Hematopoiesis

Research. University of Pennsylvania. Philadelphia, PA 2008: New York Cancer Consortium Experimental Therapeutics Symposium, New York, NY. 2008: Annual Symposium of the Samuel Waxman Cancer Research Foundation, New York, NY. 2008: Symposium on Genomics and Epigenomics of Cancer, Biogen Idec. Cambridge, MA. 2008: Chemotherapy Foundation 26th Annual Symposium, New York, NY. 2008: Montefiore Medical Center. Oncology Grant Rounds. Bronx, NY. 2008: 10th International Conference on Malignant Lymphoma. Lugano, Switzerland. 2008: ASH Highlights meeting. Seattle, WA 2008: ASH Highlights meeting. Austin, TX. 2008: University of Indiana research seminar. Indianapolis, IN. 2007: American Society of Hematology Annual Meeting – Best of ASH session. Atlanta, GA. 2007: 2007 Workshop on Myeloid Development, American Society of Hematology Annual Meeting

Atlanta, GA. 2007: Chemotherapy Foundation 25th Anniversary Symposium. New York, NY. 2007: Shanghai Institute of Hematology 20th Anniversary Symposium. Shanghai, China. 2007: Aggressive Lymphoma Symposium. Göttingen, Germany. Dr. Rita Shaknovich was post-doc

replacement. 2007: ASCO forum on DLBCL therapeutics. Aspen, CO. 2007: Heidelberger Cancer Symposium. New York, NY. 2007: Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development

and Leukemia. Annapolis, MD. 2007: Keynote speaker. Association for Molecular Pathology Annual Meeting. Los Angeles, CA. 2007: Keynote speaker. Department of Medicine Research Day – Mount Sinai School of Medicine,

New York, NY. 2007: USA-Japan Cooperative Cancer Workshop on Animal Models of Hematological

Malignancies. Kauai, HW. 2007: 2007 Lymphoma & Myeloma Meeting. New York, NY. 2007: Leeds University Department of Biology Research Seminar. Leeds, UK. 2007: FASEB Meeting on Hematologic Malignancies. Invited Speaker. Saxtons River, VT. 2007: CNIO Cancer Conference on Molecular mechanisms in lymphoid neoplasms, Madrid, Spain. 2007: Cell penetrating Peptides International Meeting. Telford, UK. 2007: University of Michigan School of Medicine. Research Seminar, Ann Arbor, MI. 2007: Montefiore Medical Center. Hematology Grand Rounds. Bronx, NY. 2007: University of Massachusetts School of Medicine. Research Seminar, Worcester, MA. 2007: Tulane University School of Medicine. Research Seminar, New Orleans, LA. 2006: 3rd International Meeting on Innovative Therapies for Lymphoma. Palermo, Sicily, Italy. 2006: American Society of Hematology Annual Meeting. Meet the Expert. Orlando, FL.

2006: Gen*NY*sys/SUNY Research Center Seminar. Albany, NY 2006: Memorial Sloan Kettering Cancer Center. Dept. of Pharmacology Research Serminar. NYC. 2006: University of Minnesota Cancer Center Seminar Series. Minneapolis, MN. 2006: Yale University School of Medicine. Hematology Research Seminar. New Haven, CT. 2006: Mount Sinai School of Medicine. Hematology/Oncology Research Seminar, New York, NY. 2006: Erasmus University. Hematology lecture series. Rotterdam, Netherlands. 2006: Cold Spring Harbor Laboratories course in Integrated Data Analysis for High Throughput

Biology. Invited Speaker. Cold Spring Harbor, NY. 2006: Mount Sinai School of Medicine. Hepatocellular Carcinoma Group Research Seminar. New

York, NY. 2006: IRIC. University of Montreal. Research Seminar. Montreal, Quebec, Canada. 2006: New York Cancer Consortium Experimental Therapeutics Symposium, New York, NY. 2006: American Society for Clinical Oncology National Meeting. Invited Speaker. Atlanta, GA. 2006: American Association for Cancer Research National Meeting. Invited Speaker, Washington

DC 2006: NimbleGen Symposium on genomic arrays. Washington DC. 2006: Keynote speaker. Fourth Annual Midwest Blood Club. Lexington, KY. 2006: Centro de Investigacion en Cancer (CIC) Universidad de Salamanca, Research Seminar,

Salamanca, Spain. 2006: Centro de Investigacion en Medicina Aplicada (CIMA). Research Seminar. Pamplona, Spain. 2006: Centro Nacional de Investigacion Oncologica (CNIO). Research Seminar. Madrid, Spain. 2006: 1st International Workshop of the German Network on Malignant Lymphomas, Cologne,

Germany 2005: American Society of Hematology National Meeting. Invited Speaker. Atlanta, Ga. 2005 American Society of Hematology National Meeting. (Post doc: Stella Ranuncolo). Atlanta,

GA. 2005: NCI Workshop on Translational Research in Epigenetics. Bethesda, MD. 2005: Argentine Society of Clinical Research National Meeting. Mar Del Plata, Argentina. 2005: University of Nebraska. Pathology Grand Rounds. Omaha, NE. 2005: Lady Davis Institute/McGill University. Research Seminar. Montreal, Quebec, Canada. 2005: Biogen-Idec. Research Seminar. Cambridge, MA. 2005: Molecular Pharmacology & Chemistry Seminar Series. Memorial Sloan Kettering Cancer

Center. New York, NY. 2005: Research Seminar. Dana Farber Cancer Institute. Boston, MA. 2005: Hematology/Oncology Grand Rounds. Weill-Cornell School of Medicine, New York, NY. 2005: Pathology Seminar Series. Weill-Cornell School of Medicine. New York, NY. 2005: NCI Think Tank on Therapeutic Targeting of Lymphoid Malignancies. Bethesda, MD. 2005: Gordon Conference on Cancer Epigenetics. Smithfield, RI. 2005: FASEB Meeting on Hematologic Malignancies. Invited Speaker. Saxtons River, VT. 2005: University of Pennsylvania. Research Seminar. Philadelphia, PA. 2005: Johns Hopkins School of Medicine. Research Seminar. Baltimore, MD. 2005: New York University. Research Seminar. New York, NY. 2005: Institute for Medical Research. North Shore/LIJ Medical Ctr. Research Seminar. Nassau,

NY. 2005: Long Island Jewish Hospital. Oncology grand rounds. Queens, NY. 2005: Moffit Cancer Center. Oncology Grand Rounds. Tampa, FL. 2005: Workshop on Clinical Translation of Epigenetics in Cancer Therapeutics. Charleston, SC. 2005: Mantle Cell Lymphoma Research Workshop. New York, NY. 2004: ECOG National Meeting. Invited Speaker. Tampa, FL. 2004: 2nd International Meeting on Innovative Therapies for Lymphoma. Palermo, Sicily, Italy. 2004: Third Mouse Models of Hematopoietic Malignancies Workshop. New York, NY. 2004: Albert Einstein College of Medicine. Internal Faculty Seminars. Bronx, NY.

2004: Albert Einstein College of Medicine, Hematology Grand Rounds Bronx, NY. 2004: Albert Einstein College of Medicine, Oncology Grand Rounds Bronx, NY. 2004: Institute of Gene Biology. Chromatin Biology Symposium. Moscow, Russia. 2004: Dartmouth University School of Medicine. Dept. of Pharmacology & Toxicology Seminar.

Hanover, NH. 2004: Columbia University Faculty Seminar, New York, NY 2004: Albert Einstein College of Medicine, Hematology Grand Rounds. Bronx, NY. 2004: Mount Sinai School of Medicine. Hematology/Oncology Grand Rounds. New York, NY 2004: University of Chicago. Division of Hematology/Oncology Grand Rounds. Chicago, IL. 2004: University of Pennsylvania. Hematology/Oncology Department. 2004 American Society of Hematology National Meeting. Plenary Session (student: Jose Polo).

San Diego, CA. 2003 FASEB Meeting on Hematologic Malignancies. Saxtons River, VT. 2003 Genomic Array Workshop. National Cancer Institute. Bethesda, MD. 2003 Argentine Society of Hematology National Meeting. Transcription Therapy. Mar Del Plata. Argentina. 2003 Argentine Society of Hematology National Meeting. APL update. Mar Del Plata. Argentina. 2003 Argentine Society of Hematology National Meeting. Breakfast with the expert – translational research. . Mar Del Plata. Argentina. 2003 ECOG National Group Meeting – Miami, FL. 2003 American Society of Hematology National Meeting. San Diego, CA. 2003 Mechanisms of Eukaryotic Transcription Meeting. Cold Spring Harbor Laboratories, NY. 2003 American Association for Cancer Research. National Meeting. Washington DC. 2003: Albert Einstein College of Medicine, Hematology Grand Rounds Bronx, NY. 2003: University of California at San Diego. Department of Cellular and Molecular Medicine.

Research Seminar. San Diego, CA. 2003: New York Hospital Division of Hematology/Oncology. Grand Rounds. . New York, NY. 2003: Angel Roffo Oncology Research Institute of the University of Buenos Aires. Special

Research Seminar. Buenos Aires, Argentina. 2003: Columbia University Department of Genetics and Development Research Seminar. New

York, NY. 2003: Cancer Institute of New Jersey Hematologic Malignancies Research Seminar. New

Brunswick, NJ. 2003: Albert Einstein College of Medicine Medicine Grand Rounds, Bronx, NY. 2002 Argentine Society of Hematology. Buenos Aires, Argentina. 2002 Instituto Lanari, Universidad Nacional de Buenos Aires. Research Seminar. Buenos Aires,

Argentina. 2002 American Society of Hematology National Meeting (Post-Doc: Nathalie Chevalier). Philadelphia, PA. 2002 New York Regional Stem Cell Meeting. Wave Hill, NY. 2002 Universidad Nacional de Quilmes. Research Seminar. Buenos Aires, Argentina. 2002 Argentine Consulate. New York, NY. 2001 INSERM Research Institute, Hôpital St. Louis. Research Seminar. Paris, France. 2001 Albert Einstein College of Medicine. Albert Einstein Cancer Center Seminar. Bronx, NY. 2001 New Jersey Cancer Institute - UMDNJ-RWJSM. Research Seminar. New Brunuswick, NJ. 2001 Center for Medical Education and Clinical Research. Research Seminar. Buenos Aires,

Argentina. 2001 Yale School of Medicine Hematology Section Research Seminar. New Haven, CT. 2001 American Society of Hematology. National Meeting. Orlando, FL. 2001 IX International Conference on Differentiation Therapy. Rome. Italy. 2001 New York Regional Stem Cell Meeting. Wave Hill, NY. 2001 Second Argentine-American Medical Society Conference. New York City.

2001 Fourth International Meeting on Molecular Aspects of Myeloid Stem Cell Development. Annapolis, Md.

2000 Derald Ruttenberg Cancer Center Research . Mount Sinai School of Medicine. New York, NY.

2000 Division of Medical Oncology Grand Rounds. Mount Sinai Medical Center. New York, NY. 2000 University of Buenos Aires School of Medicine. Department of Pharmacology. Research

Seminar. Buenos Aires, Argentina. 2000 Invited Speaker, National conference on “Controversies in Management of Acute

Leukemias”. Buenos Aires, Argentina (2 lectures). 2000 Oncology/Radiation Oncology Grand rounds. NYU Medical Center. 2000 American Society of Hematology. National Meeting. San Francisco, CA. Workshop on

Myeloid Development. 2000 American Society of Hematology. National Meeting. San Francisco, CA. 2000 New York Regional Stem Cell Meeting. Wave Hill, NY. 2000 American Association for Cancer Research. National Meeting. San Francisco, CA.

February 20, 2015 Signature Date